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ABSTRACT
Mitogen-activated protein kinases (MAPKs) are important signal transducers that regulate diverse
cellular functions. The MAPK family consists of three well characterized subfamilies; the extracellular
signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs), and the p38 MAPKs. MAPKs
transmit extracellular signals to changes in gene expression through signal responsive transcription
factors. Activator protein-1 (AP-1), a nuclear transcription factor activated during embryonic
development, is one of the best studied targets for MAPK signaling. AP-1 is a dimeric protein complex
that is composed of Jun and Fos proteins. Even though much is known about the role of AP-1 in various
cellular states, many of its functions have remained unsolved. The aim of the studies presented here was
to clarify the role of MAPKs and AP-1 during cellular differentiation and survival by using experimental
cell culture models for cardiomyocyte, neuronal and megakaryocytic differentiation.
Depending on the cellular context, the MAPK-mediated regulation and function of AP-1 is different.
During cardiomyocyte differentiation of embryonal carcinoma cells, our studies revealed that AP-1
transcription factor is regulated by p38 and ERKs, whereas cell proliferation is controlled by JNK. Only
p38 MAPK is essential for the differentiation response. By generating dominant-negative c-Jun cell
lines, we demonstrated that c-Jun regulates cardiomyocyte differentiation through p38 MAPK.
On the other hand, ERK appears to be essential during the megakaryocytic differentiation response of
leukemia cells. The role of AP-1 as a mediator of ERK signaling during megakaryocytic differentiation
was demonstrated by c-fos siRNAs and dominant negative AP-1, which suppress the expression of α
2
β
1
integrin on the surface of megakaryocytes. The importance of c-Jun and c-Fos in cell differentiation
was further supported by studies on neuronal differentiation of pheochoromocytoma (PC12) cells,
where c-Fos was required and c-Jun sufficient for neuronal differentiation. Furthermore, we implicate
that the activation kinetics of MAPK affect the AP-1 composition and consequently cell fate.
The role of c-Jun both as an executor and inhibitor of differentiation and apoptosis was determined in
PC12 cells differentiating into neuronal cells. In undifferentiated cells, c-Jun protects against apoptosis
and triggers neuronal differentiation. By analyzing c-Jun in more detail, we showed that during neuronal
differentiation c-Jun functions as a conventional transcription factor, involving dimerization, DNA-
binding and transcriptional activation. However, the antiapoptotic function of c-Jun is not mediated by
conventional AP-1 activity, since mutants with defective dimerization and DNA-binding domains could
rescue cells from apoptosis, although they could not induce neuronal differentiation. In contrast,
subsequent studies showed that another AP-1 family member, ATF-2, acted as an executor of apoptosis
in undifferentiated cells.
Taken together, our data provide information about the complex regulation of AP-1 transcription factor
during cellular differentiation and survival. The abundance of different AP-1 proteins within a cell, the
cell type, differentiation stage, and nature of stimulus have a great impact on whether the cell proliferates,
differentiates, or dies.
ABSTRACT
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REVIEW OF LITERATURE
1. Signal transduction
Cells obtain information from their environment that influences cell proliferation, differentiation, cell
movement and cell death. These are important events during embryonic development, wound healing
and in the regulation of the immune system. A number of cell surface receptors and signaling molecules
have been identified to transmit extracellular signals to changes in gene expression. The alterations in
gene expression are controlled by transcription factors, which are located into the cell nucleus in order
to activate gene transcription. A simplified view of cellular signaling induced by mitogens and stress and
the different outcomes is shown in Figure 1. The type and differentiation state of a cell play an extremely
important role in regulating whether a molecule promotes or inhibits the cellular response. Cells in
multicellular organisms must sense the presence of neighboring cells and hormones when deciding
about their fate. This requires transfer of information from the sensor, i.e. receptor, to the target protein.
Signal transduction or cell signaling involves the mechanisms by which transfer of biological information
occurs.
Figure 1. Cellular signaling. A schematic view of intracellular signaling cascades represented by mitogen-activated
protein kinases (MAPKs) ERK, JNK and p38. The cascades are activated by various extracellular events through
phosphorylation leading to different cellular responses.
1.1. Signaling during cell growth, differentiation, and apoptosis
Growth factors define the size of various tissues by creating a balance between cell proliferation and
programmed cell death, apoptosis. Normal cells usually need growth factors to stay alive, whereas
transformed cells can evade this requirement. Cell fate is controlled by numerous signaling pathways
which transmit signals mediating proliferation, survival or death. In order to study the complex network
of signaling pathways, they have to be dissected into fractions, which can be studied individually to
define the precise role of separate pathways. Signaling pathways rarely transmit signals just within their
own pathway, but are influenced by other pathways, creating an extremely complex network of signaling
cascades.  There  are  many  signaling  pathways  that  are  fundamental  during cell survival.
REVIEW OF LITERATURE
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These include the phosphatidylinositol 3-kinase (PI3K)/Akt, the Ras/mitogen-activated protein kinase
(MAPK),  the Janus kinase (Jak)/signal transducers and activators of transcription (STAT) pathways,
transforming growth factor β (TGFβ)/Smad signaling, Wnt/Frizzled and nuclear factor κB (NF-κB)
signaling, just to mention some. All these pathways transmit signals that mediate survival of cells of
different origins (Hunter, 2000).
1.2. Transcriptional regulation of gene expression
Signaling pathways activate inducible transcription factors in the cell nucleus and lead to changes in
gene expression. Transcriptional regulation of eukaryotic gene expression is a multistep process involving
distinct nuclear RNA polymerases, RNA polymerase-specific initiation factors, various transcription
factors that bind to specific DNA sequences, and cofactors that either modify the chromatin structure
or regulate the function of the preinitiation complex. The core promoter, which is located immediately
upstream of the initiation site for transcription, is the binding site for the basal transcriptional machinery.
The basal transcriptional machinery consists of RNA polymerase II (RNAPII) and general transcription
factors, such as TFIID and TFIIA. TFIID is a multiprotein complex consisting of TATA-binding protein
(TBP), which binds to the TATA-box in the core promoter, and its associate factors. TFIID bound to
DNA allows TFIIA and TFIIB binding and this preinitiation complex allows RNAPII to enter and
initiate transcription. Regulatory factors can bind to distal control elements on the promoter and modify
preinitiation complex assembly. Coregulators, for instance histone-modifying factors, such as histone
acetyltransferases (HATs), can modify chromatin structure by assisting additional factor interactions or
cofactors can modify the function of the basal transcriptional machinery by direct interaction after
chromatin remodeling (reviewed by Roeder, 2005). Extracellular signals activate inducible transcription
factors, such as activator protein-1 (AP-1).  The transcriptional mechanisms mediating the pleiotropic
effects of AP-1 are largely unknown. They involve post-translational modifications and protein-protein
interaction at promoters of target genes. Specific transcription factors interact with each other,
coactivators or repressors and chromatin remodeling proteins forming multiprotein complexes that
regulate the activity of the basal transcriptional machinery.
2. Mitogen activated protein kinases (MAPKs)
Mitogen-activated protein kinases (MAPKs) are the most thoroughly studied signal transduction systems.
They have been shown to participate in diverse cellular events, including cell growth, differentiation,
movement, and death. The MAPKs are extremely conserved in eukaryotes throughout evolution and
they connect cell-surface receptors to regulatory targets within the cell. MAPKs also respond to various
forms of physical and chemical stress, and thereby control cell survival and adaptation to different
cellular fates. MAPKs are typically organized as a three-kinase cascade consisting of a MAPK, MAPK
activator (MAPKK, MKK, or MEK) and a MAPKK activator or MEK kinase (MAPKKK or MEKK)
(English et al., 1999a). Transmission of signals is achieved by sequential phosphorylations. MAPKs
serve as phosphorylation substrates for MAPKKs, and MAPKKs as substrates for MAPKKKs. MAPKs
are activated by dual phosphorylation of threonine and tyrosine residues within a T-X-Y motif (Ray and
Sturgill, 1988). Mammals contain three well characterized subfamilies of MAPKs. These include the
extracellular signal-regulated kinases (ERKs) (Boulton and Cobb, 1991), the c-Jun N-terminal kinases
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11
(JNKs)  (Kyriakis  et  al.,  1994),  and  the  p38  MAPKs  (Han  et  al., 1995)  (Figure  2). The  individual
MAPK pathways can in general signal independently of each other, but the biological role of a signal
determines which MAPK pathway is activated. ERKs generally regulate cell growth and differentiation,
whereas JNKs and p38 MAPKs regulate stress responses.
Figure 2. Schematic overview of mitogen-activated protein kinase (MAPK) signaling cascades. The MAPK module
contains a MAPK kinase kinase (MAPKKK), which phosphorylates a MAPK kinase (MAPKK), which activates a
MAPK. The activated MAPKKKs can activate one or several MAPKs. MAPK activation is followed nuclear translocation
and by phosphorylation of transcription factors, i.e. AP-1, ATF-2, Elk-1, MEF2C in the cell nucleus. These downstream
targets control cellular responses, such as cell growth, differentiation, and apoptosis (Modified from Hazzalin and
Mahadevan, 2002).
Originally, the MAPK signaling cascades were thought to function as linear signaling pathways.  However,
it is now obvious that signaling between MAPK pathways and other signaling molecules occurs. In
addition to being activated by phosphorylation, MAPKs are regulated by protein phosphatases that
inactivate MAPKs and regulate the strength and duration of MAPK activity (Keyse, 1998). Furthermore,
scaffold proteins contribute to the specificity of signal transduction. Subcellular targeting of the stress-
activated JNK-pathway is achieved by association with Jun-interacting proteins (JIPs), scaffold proteins
that prevent nuclear translocation of JNK and inhibit JNK-regulated gene expression (Yasuda et al.,
1999).
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2.1. ERK MAPKs
ERKs, which consist of ERK1 and ERK2, were the first MAPKs to be identified (Boulton and Cobb,
1991). The ERKs are widely expressed and involved in cell proliferation processes such as meiosis and
mitosis. ERKs are activated by growth factors, cytokines, viral infections and ligands for G-protein
coupled receptors, transforming agents, and carcinogens (Boulton et al., 1991). The ERK activation
involves receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR) and
platelet-derived growth factor receptor (PDGFR), signaling through the small guanosine triphosphate
(GTP) binding protein Ras. The GTP form of Ras binds to MAPKKK c-Raf-1 at the plasma membrane.
Activated c-Raf-1 phosphorylates MAPKKs MEK1 and MEK2 and stimulates their ability to activate
ERK1 and ERK2 by phosphorylation (Burgering and Bos, 1995). Cells that are transformed with an
oncogenic form of Ras show increased MEK1 activity, suggesting that Ras and c-Raf-1 prefer signaling
to ERKs through MEK1 (Jelinek et al., 1994). There are two additional members of the Raf-family; A-
Raf and B-Raf, which are activated by Ras and regulate MEK activity (Vaillancourt et al., 1994; Wu et
al., 1996). Another MAPKKK that activates MEK is the serine-threonine kinase Mos, a regulator of
meiosis during germ cell development (Chen and Cooper, 1995). The ERK activity is also controlled by
a scaffold protein, MEK partner-1 (MP1). MP1 functions as a regulator of MAP kinase signaling by
binding to MEK1 and ERKs (Schaeffer et al., 1998).
Once ERK1 and ERK2 are activated they phosphorylate many proteins, for example p90rsk, cytosolic
phospholipase A
2
, EGFR, carbamoyl phosphate synthetase II (CPSII,), but also c-Raf-1 and MEK1 and
thereby regulate their own signaling pathway (Burgering and Bos, 1995). Activated ERKs translocate
to the nucleus where they phosphorylate and activate transcription factors including activator protein-
1 (AP-1), Elk-1, switch-activating protein-1a (SAP-1a), estrogen receptor, and STAT proteins (Janknecht
et al., 1993; Janknecht et al., 1995; Kato et al., 1995; Ihle, 1996).
Other forms of ERKs (ERK3, ERK4, and ERK5) have been characterized, but their regulation has
remained unclear (Boulton et al., 1991; Zhu et al., 1994; Zhou et al., 1995). ERK5, also called big
MAP kinase (BMK), and its activator MEK5 have the same dual phosphorylation motif as other ERK
family members, but they also possess very distinct features suggesting they might belong to a novel
MAPK signaling pathway (Zhou et al., 1995). More recent studies reveal that ERK5 is activated by
MEKK3 via MEK5 (Chao et al., 1999). ERK5 is activated by serum and epidermal growth factor
(EGF), and contributes to EGF-induced cell proliferation and cell cycle progression as well as Ras-
dependent transformation (Kato et al., 1997; Kato et al., 1998; English et al., 1999b). Furthermore,
ERK5 has an essential role in cardiovascular development since erk5 deficient mice have defects in
cardiac development leading to embryonic death (Regan et al., 2002). erk5-/- mice have similar
phenotypes to Mekk3-/- mice,  Mekk3 being the upstream kinase of ERK5. Mice lacking the erk5
substrate, MEF2C, also have a similar phenotype (Yang et al., 2000).
ERKs are stimulated by various mitogenic stimuli, and sustained activation of ERKs is necessary for
cell cycle progression. Cell cycle transition also depends on cyclin-dependent kinase (CDK) activation.
ERK activity leads to upregulation of cyclin D1 and downregulation of CDK inhibitor p27Kip1 in NIH
3T3 cells (Delmas et al., 2001). Furthermore, expression of constitutively active MEK, the immediate
upstream activator of ERK1 and ERK2, stimulated PC12 cell neuronal differentiation and transformed
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NIH 3T3 cells leading to tumor formation in mice (Cowley et al., 1994; Mansour et al., 1994). The
activation kinetics of ERK signaling pathways have been linked with specific biological outcomes. In
PC12 cells, sustained activation of ERKs results in neuronal differentiation, whereas transient activation
does not (Marshall, 1995). Recently, c-Fos has been suggested to be a molecular sensor for ERK signal
duration. Sustained ERK activity phosphorylated c-Fos resulting in protein stabilization, whereas transient
ERK activity resulted in expression of unstable c-Fos, which was rapidly degraded (Murphy et al.,
2002). In addition, ERK prevents apoptosis of cerebellar granular cells through ribosomal S6 kinase
(RSK), which inactivates the pro-apoptotic protein Bad (Bonni et al., 1999). ERK1-deficient mice are
viable, with a modest defect in T-cell development (Pages et al., 1999). Mek1-deficient mice have more
striking defect and die in utero due to defects in placental vascularization (Giroux et al., 1999) (Table
1).
Table 1. Phenotypes of MAPK and MAPKK knock-out mice
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Disrupted gene Phenotype Affected organ/ cell type References
ERK1 Defective T-cell development T-cells (Pages  et al. , 1999)
ERK2 Not characterized
JNK1 Defective T-cell 
differentiation to Th2 cells
T-cells (Dong et al. , 1998)
JNK2 Defective T-cell 
differentiation to TH1 cells
T-cells (Yang et al. , 1998; 
Sabapathy et al. , 1999)
JNK1 and JNK2 IL-2 overproduction, neural 
tube closure
T-cells, brain (Kuan et al. , 1999; Dong 
et al. , 2000)
JNK3 Resistant to excitotoxic 
neuronal apoptosis
Brain (Yang et al. , 1997)
p38α Placental defect, insufficient 
production of erythropoietin
Placenta, trophoblasts, red 
blood cells
(Adams et al. , 2000; 
Tamura et al. , 2000)
ERK5 Embryonic lethal              
Vascular and cardiovascular 
defects
Heart, blood vessles (Regan et al. , 2002)
MEK1 Embryonic lethal            
Defective placental 
vascularization
Placenta (Giroux et al. , 1999)
MKK3 Defective IL-12 production Macrophages (Lu et al. , 1999)
MKK4 Embryonic lethal        
Defective liver development
Hepatocytes (Ganiatsas et al. , 1998)
MKK6 Impaired apoptosis of 
thymocytes
Thymocytes (Tanaka et al. , 2002)
MKK7 Embryonic lethal Hepatocytes (Dong et al. , 2000; Wada 
et al. , 2004)
2.2. JNK MAPKs
The JNKs are the classical stress-activated MAPKs. The JNK cascade was discovered by studies on the
cooperation between oncogenic Ras and activation of AP-1 transcription factor by ultraviolet irradiation
(Derijard et al., 1994; Kyriakis et al., 1994). There are three distinct JNKs; JNK1 and JNK2 are
ubiquitously expressed, whereas the expression of JNK3 is restricted to the brain, heart, and testis
(Gupta et al., 1996).
JNKs are activated by phosphorylation of threonine and tyrosine by MKK4 (or SEK1) and MKK7. The
MKK7 protein kinase is primarily activated by cytokines, such as tumor necrosis factor (TNF) and
interleukin-1 (IL-1), whereas MKK4 is mainly activated by environmental stress (Tournier et al., 1999)
(Moriguchi et al., 1995). MKK4 and MKK7 are localized both in the cytosol and in the nucleus and
may possibly activate JNK both in the cytoplasm and in the nucleus. In addition, JNK activity is regulated
by scaffold proteins, including the JNK-interacting proteins (JIPs) JIP1 and JIP2. JIPs also bind to
MKK7 and a variety of protein kinases and function both as positive and negative regulators of JNK
(Yasuda et al., 1999).
The JNK pathway is activated in response to stress stimuli. The cellular context seems to be of importance,
since JNK has been proposed to play a role in both apoptosis and cell survival. Pro-apoptotic signaling
by JNK is supported by data where c-Myc is phosphorylated by JNK, inducing apoptosis (Noguchi et
al., 1999). In addition, JNK seems to regulate Fas-L expression and p53 stabilization, and may contribute
to apoptosis by these pathways (Milne et al., 1995; Faris et al., 1998). Mouse embryonal fibroblasts
isolated from Jnk1-/-Jnk2-/- embryos have severe defects in stress-induced apoptosis, due to failure of
activation of effector caspases (Tournier et al., 2000). However, these fibroblasts have no defects in
Fas-induced apoptosis, indicating that JNK is required for mediating some, but not all, apoptotic
pathways. Even if JNK contributes to some apoptotic responses, it is often activated by stimuli which
do not induce apoptosis. Kinetics of JNK activation often correlates with the response as well; sustained
activation is associated with apoptosis, whereas transient activation is not. The best evidence for JNK
signaling in cell survival comes from knock-out studies (Table 1). Jnk1-/-, Jnk2-/- double knock-out
embryos have increased apoptosis in the developing forebrain (Kuan et al., 1999). Deficiency in only
JNK1 or JNK2 does not affect development. JNK1 or JNK2 deficient mice appear to be normal, but are
immunodeficient due to defects in T cell function. JNK does not appear to be essential for T cell
activation, but is required for effector T cell function (Dong et al., 2000). However, both MKK4 and
MKK7 are essential for embryonal development. MKK4-/- lethality is due to liver cell apoptosis
(Ganiatsas et al., 1998), whereas the cause of MKK7 lethality is impaired proliferation of hepatocytes,
due to defective cell cycle progression and cellular senescence (Wada et al., 2004). In some cases
MKK7 may complement MKK4 deficiency, because MKK4 disruption does not block JNK activation
in T-cells (Dong et al., 2000).
Moreover, JNK plays an important role in tumor cells. Ras-induced tumorigenesis is suppressed by
mutating the JNK phosphorylation sites of c-Jun (Behrens et al., 2000). JNK is also constitutively
activated in several tumor cell lines and many transforming oncogenes are JNK-dependent (Xu et al.,
1996; Xiao and Lang, 2000; Antonyak et al., 2002).
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2.3. p38 MAPKs
p38 MAPK was identified as a 38 kDa protein that became tyrosine phosphorylated upon
lipopolysaccharide treatment of monocyte cell lines (Han et al., 1994; Han et al., 1995). There are four
isoforms of p38 MAPK; p38α, β, γ, and δ (Jiang et al., 1996; Li et al., 1996; Jiang et al., 1997). Both
JNK and p38 are activated by dual phosphorylation in response to cellular stress (Raingeaud et al.,
1995). Two p38 MAPK activating kinases have been identified; MKK3 and MKK6 (Derijard et al.,
1995; Han et al., 1996). MKK4, which activates JNK, also stimulates p38 MAPK activity (Derijard et
al., 1995). MKK6 activates all isoforms, whereas MKK3 activates p38α, γ, and δ, and MKK4 activates
only p38α (Enslen et al., 1998).
p38 MAPKs seem to play important roles in many cellular processes additional to stress responses.
These include cell proliferation, differentiation, and survival. The importance of p38α in adipocyte
differentiation has been demonstrated by dominant-negative and constitutively active mutants of p38α
(Engelman et al., 1998; Engelman et al., 1999). During myogenic and cardiomyogenic differentiation
p38 MAPKs play essential roles by regulating MyoD and myocyte-enhancer factor C (MEF2C)
transcription factors, which are essential for muscle differentiation (Zechner et al., 1997; Zetser et al.,
1999). Furthermore, neuronal differentiation of PC12 cells appears to be mediated by p38 MAPKs as
well as ERKs (Morooka and Nishida, 1998). p38α-deficient mice die as embryos at midgestation due
to massive reduction of the myocardium and malformation of blood vessels in the head (Adams et al.,
2000). These are secondary effects to insufficient oxygen and nutrient transfer across the placenta.
p38α-/- mice also have a defect in erythropoiesis (Tamura et al., 2000). p38 MAPKs have been suggested
both as positive and negative regulators of cell survival. In PC12 cells p38 participates in nerve growth
factor (NGF) withdrawal-triggered apoptosis (Xia et al., 1995). Conversely, p38 protects primary rat
cardiomyocytes from anisomycin-induced apoptosis (Zechner et al., 1998). In cell proliferation, p38
MAPKs have opposing roles depending on the cellular context. p38 is essential for fibroblast growth
factor-2 (FGF-2)-induced proliferation of Swiss 3T3 cells, but it inhibits cell cycle progression in NIH
3T3 fibroblasts (Molnar et al., 1997; Maher, 1999). To date, only p38α-deficient mice have been
reported (Table 1).
2.4. Transcriptional regulation by MAPKs
MAPK signaling cascades transmit extracellular signals into the cell nucleus, where transcription factors
mediate changes of gene expression. MAPKs are activated by phosphorylation in the cytoplasm and
translocated into the nucleus, where they induce phosphorylation of transcription factors, co-activators
and nucleosomal proteins. Some transcription factors also bind to other transcription factors.
Transcription factors can be selectively activated or deactivated by other proteins, often as the final step
in signal transduction (Martinez, 2002). Immediate-early genes are genes that are rapidly and transiently
induced without a requirement for new protein synthesis. Many immediate-early genes encode
transcription factors. AP-1 transcription factor is one of the best studied MAPK targets. AP-1 is composed
of proteins belonging to the Jun and Fos families (see below). c-jun and c-fos are immediate-early
genes. MAPK signaling pathways regulate AP-1 activity by increasing transcription and by
phosphorylation of AP-1 proteins (see below). Another factor regulated by MAPKs is the ternary
complex factor family (TCF)/Elk-1. ERK phosphorylates Elk-1 and causes increased formation of the
serum response element (SRE), ternary complex, and activates transcription of c-fos (Gille et al., 1992).
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3. AP-1 transcription factor
3.1. AP-1 transcription factor family
Activator protein-1 (AP-1) is one of the first mammalian sequence-specific transcription factors
recognized (Angel et al., 1987a; Bohmann et al., 1987). AP-1 was first known as a 12-O-tetradecanoyl-
phorbyl-13-acetate (TPA) inducible transcription factor, since the TPA response element (TRE) was
identified as a binding site for AP-1 in many cellular and viral genes (Angel et al., 1987a). AP-1 belongs
to the dimeric basic region-leucine zipper (bZIP) protein group composed of Jun, Fos, and activating
transcription factor (ATF) protein family members. AP-1 transcription factor is a dimer and the complexity
of AP-1 begins with the transcription factor itself. AP-1 is composed of many different combinations of
hetero- or homodimers and the composition of AP-1 determines the genes that it regulates.
AP-1 is regulated on multiple levels (Figure 3). The expression of AP-1 proteins is regulated by controlling
the transcription of their genes. AP-1 function is also dependent on dimer composition in the DNA-
binding complex. In addition, AP-1 proteins are regulated by posttranslational modifications. The most
common posttranslational modification known to regulate protein activity is phosphorylation. AP-1
proteins are phosphorylated by MAPKs. Furthermore, AP-1 proteins are regulated by ubiquitination,
which targets proteins for proteasome-mediated degradation.
Figure 3. The activation of AP-1 is regulated at multiple levels. Increase in expression, MAPK-dependent
phosphorylation, and dimerization lead to stabilization of the AP-1 complex and subsequently to AP-1 activation.
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3.2. c-Jun
c-Jun is the best characterized AP-1 component. The c-jun proto-oncogene was originally isolated
from avian sarcoma virus 17 in 1987 as a cellular homolog of the retroviral oncogene v-jun (Maki et al.,
1987), and shortly thereafter it was identified as a major component of AP-1 (Bohmann et al., 1987). c-
Jun is a nuclear protein which is expressed in many cell types at low levels, but its expression is upregulated
by growth factors, cytokines, and UV irradiation. c-Jun is fairly conserved among different species.
3.2.1. Structure of c-Jun
Human c-jun is a 3.1 kb proto-oncogene, which, like many immediate-early genes, lacks introns (Hattori
et al., 1988). The c-Jun protein is composed of 334 amino acids. It has three main domains that are
particularly well conserved among the different Jun and Fos family members; the leucine zipper (bZIP)
domain, the basic region and the transactivation domain (Figure 4). The bZIP, domain containing two
parallel α-helixes that form a coiled coil in the C-terminus, is responsible for the dimerization of AP-1
proteins (Landschulz et al., 1988). The characteristic feature of the leucine zipper is a periodic repeat
of leucines located at every seventh amino acid forming interacting hydrophobic ridges in the dimer.
The very conserved positively-charged basic region is located immediately N-terminally to the leucine
zipper and mediates DNA binding (Gentz et al., 1989; Turner and Tjian, 1989). The DNA-binding
domain contains the nuclear localization signal (NLS), which is identical in both v-Jun and c-Jun (Chida
and Vogt, 1992). Within the transactivation domain in the N-terminus are the MAPK phosphorylation
sites. The N-terminus of c-Jun contains also a δ-domain, which is the docking site for JNK and mediates
ubiquitin-dependent degradation of c-Jun (Treier et al., 1994).
Figure 4. Structure of Jun and Fos proteins. The main domains and phosphorylation sites are shown. Leucine zipper
(bZIP) is responsible for dimerization, basic domain (BD) is responsible for DNA binding, transactivation domain
(TAD) is responsible for transactivation, δ-domain in c-Jun is the binding site for JNK, and DEF domain in c-Fos is the
docking site for ERK (modified from Hess et al., 2004).
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3.2.2. Expression of c-Jun
c-jun is an immediate-early gene, and is activated rapidly and transiently without the need for new
protein synthesis. Cytokines, growth factors, environmental stress, bacterial and viral infections, and
oncogenes activate c-jun and induce its expression in various cellular contexts. The growth-promoting
activity of c-Jun is mediated by upregulation of positive cell cycle regulators. During fibroblast
proliferation c-jun negatively regulates p53 expression. c-jun has also been implicated to play a role in
the control of the cell cycle by activating the cyclin D1 promoter during the M-G
1
 transition (Schreiber
et al., 1999; Bakiri et al., 2000). c-jun is expressed throughout organogenesis in developing cartilage,
gut and the central nervous system in postmitotic motor neurons (Wilkinson et al., 1989). Expression
in both proliferating and differentiating cells suggests that c-jun is associated with both cell proliferation
and differentiation.
3.2.3. Activation and regulation of c-Jun
As for all bZIP transcription factors, dimerization of c-Jun is required prior to binding to DNA. c-Jun
forms homodimers, or heterodimers with other Jun, Fos or ATF proteins. Jun-Fos heterodimers are
more stable than Jun-Jun homodimers (Smeal et al., 1989). The leucine zipper domain is required for
dimerization. (Landschulz et al., 1988; Turner and Tjian, 1989). The Jun-Fos dimers bind with the
highest affinity to the TRE element and with slightly lower affinity to cAMP response element (CRE),
whereas Jun-ATF dimers bind preferentially to the CRE (van Dam and Castellazzi, 2001).
Originally, AP-1 activity was induced by TPA tumor promoters. The c-Jun enhancer contains two AP-
1 binding sites, one of which has been reported to mediate positive autoregulation of the c-jun gene by
c-Jun (Angel et al., 1988). c-jun induction is usually mediated through two TPA-response elements.
These are preferentially recognized by c-Jun-ATF-2 heterodimers. However, the most important
regulation of c-Jun is phosphorylation. Phosphorylation can influence the activity of a protein by affecting
the DNA-binding, stability, ability to interact with other proteins, and transactivation potential. c-Jun is
phosphorylated at serines 63 and 73 and threonines 91 and 93 within the transactivation domain (Figure
4). MAPK-dependent phosphorylation of these sites stimulates transcriptional activation of c-Jun (Smeal
et al., 1991) (Derijard et al., 1994). However, the different JNK isoforms have distinct roles in regulating
c-Jun activation. JNK1 contributes more to c-Jun phosphorylation, activation and stabilization in
fibroblasts after cell stimulation, whereas in unstimulated cells JNK2 appears to be responsible for
targeting c-Jun for degradation (Sabapathy et al., 2004). Serines 63 and 73 are also phosphorylated by
ERK1/2 in PC12 cells and fibroblasts (Leppä et al., 1998; Morton et al., 2003). c-Jun is phosphorylated
at threonines 231 and 239 and serines 243 and 249 located proximal to the DNA-binding domain in the
C-terminus (Boyle et al., 1991). These sites are dephosphorylated during c-Jun activation and represent
inhibitory phosphate groups (Papavassiliou et al., 1995). Activation of c-Jun requires phosphorylation
of serines 63 and 73, as well as dephosphorylation of at least one of the C-terminal sites. In addition, it
has been reported that c-Jun is phosphorylated by glycogen synthase kinase 3 (GSK3) at threonine 239
and serine 249 located proximal to the DNA-binding domain, inhibiting binding of c-Jun to DNA
(Boyle et al., 1991). Also serine 243 is phosphorylated in response to lipopolysaccharides by an unknown
protein kinase (Morton et al., 2003). Phosphorylation of c-Jun stimulates transcriptional activity by
recruiting co-activator CREB-binding protein (CBP). CBP binds to  the  N-terminal  activation  domain
of  c-Jun  and  connects  the  phosphorylated  activation  domain  to  the  basal transcriptional machinery
REVIEW OF LITERATURE
19
(Bannister et al., 1995). Connection to the basal transcriptional machinery is further supported by
results which show that c-Jun binds to a TATA-binding protein-associated factor, TAF7. TAF7 favors
interaction with DNA-bound phosphorylated c-Jun, and consequently represents a cofactor that mediates
extracellular signals into changes in target gene expression (Munz et al., 2003). More recently, c-Jun
has been shown to interact with the transcriptional coactivator DNA topoisomerase I (Topo I) (Mialon
et al., 2005). c-Jun-Topo I-interaction is JNK-dependent and regulates EGFR expression during
proliferation of transformed fibrosarcoma cells. Topo I affects transcriptional regulation through assembly
of the TFIID-TFIIA complex. TFIID delivers TBP to TATA-less promoters, as the EGFR gene promoter.
Phosphorylation of serines 63 and 73 and threonines 91 and/or 93 is thought to help inducible transcription
factor interaction with the basal transcriptional machinery or with coactivators, such as histone
acetyltransferases (HATs). Phosphorylation-dependent binding of a coactivator is not the only way to
transcriptionally activate c-Jun. Phosphorylation might also release transcriptional inhibitors such as
histone deacetylases (HDACs) (Khochbin et al., 2001). In the absence of JNK signaling, HDAC3
inhibits c-Jun activity by interacting with the N-terminal region of c-Jun. JNK-dependent phosphorylation
of c-Jun reduces the repression and increases the transcriptional activity of c-Jun. The repression can
also be relieved without JNK in a phosphorylation-independent way (Weiss et al., 2003). Correspondingly,
interaction of c-Jun with CBP and the co-factor RHII/Gu-RNA-helicase does not require phosphorylation
of c-Jun. c-Jun interacts with RHII/Gu during anisomycin treatment and c-Jun-mediated neuronal
differentiation of PC12 cells and is likely to mediate c-Jun-associated promoter activation and mRNA
synthesis (Westermarck et al., 2002). The collagenase promoter, activated by c-Jun, is repressed by
E1A. The adenovirus E1A oncoprotein regulates gene expression through interaction with coactivators,
such as CBP. The repression depends on c-Jun acetylation, which is mediated by CBP (Vries et al.,
2001). Acetylation of proteins involved in transcriptional regulation is an important regulatory mechanism
leading to changes in protein interactions and DNA binding, resulting in increased or decreased
transcription (Sterner and Berger, 2000). CBP interacts with the transactivation domain of c-Jun and
stimulates the collagenase promoter through acetylation of histones, making the chromatin more available
for transcription. E1A directs the acetylation towards the DNA-binding domain of c-Jun and its acetylation
leads to repression of the collagenase promoter. Another AP-1 cofactor that increases the specificity of
AP-1 dependent transcription is the Jun activation domain-binding protein 1 (JAB1). JAB1 binds to c-
Jun and enhances the DNA binding of c-Jun-containing AP-1 complexes (Chamovitz and Segal, 2001).
In addition to phosphorylation, the function of c-Jun in vivo is further regulated by ubiquitination and
sumoylation. Ubiquitination targets proteins for proteasomal degradation, whereas sumoylation regulates
the subcellular localization and stability of proteins and may control transcriptional activation or DNA-
binding abilities of transcription factors. JNK binds to the δ-domain of c-Jun in normally growing cells
and targets the protein for ubiquitination. Following stress stimuli, MAPK-mediated phosphorylation
of c-Jun is accompanied by a reduction in c-Jun ubiquitination and consequent stabilization of the
protein (Treier et al., 1994; Fuchs et al., 1996; Musti et al., 1997).  SUMO-1 is a ubiquitin-like protein
that targets proteins analogously to the ubiquitin-proteasome pathway. Despite the  homology  and
similar  manner  of  action,  sumoylation  does  not  target  proteins  for  degradation.
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Sumoylation regulates c-Jun transcriptional activity in a negative fashion. In contrast to IκBα, in which
the roles of ubiquitination and sumoylation are opposite, SUMO-1 does not antagonize ubiquitination
of c-Jun (Desterro et al., 1998; Muller et al., 2000). Sumoylation is a reversible process, and the
desumoylation is mediated by SUMO-specific proteinases (SENPs). Both SENP1 and SENP2 can
regulate the transcriptional activity of c-Jun. The transactivation of CBP is increased by SENP1-mediated
desumoylation, which enhances the transcriptional activity by c-Jun (Cheng et al., 2005). An isoform of
SENP2, SuPr-1, has been identified as a transcriptional regulator of c-Jun independently of c-Jun
phosphorylation (Best et al., 2002). SuPr-1 affects c-Jun activity indirectly, probably by shifting the
localization of other coactivators and/or repressors.
3.3. Other Jun proteins
JunB
Ryder and co-workers demonstrated that there is a jun family of genes by cloning junB (Ryder et al.,
1988). Similar to c-Jun, JunB plays a role in regulating the gene expression in response to growth
factors. JunB has a very similar primary structure and DNA-binding specificity to c-Jun, except for the
transactivation domain. JunB lacks the N-terminal serine residues, serines 63 and 73, which are crucial
for MAPK-dependent phosphorylation. However, threonines 102 and 104 are phosphorylated by JNK
and these sites are corresponding to threonines 91 and 93 in c-Jun (Kallunki et al., 1996; Li et al.,
1999). JunB and c-Jun differ greatly in their capacities to activate transcription. Whereas c-Jun is an
efficient activator of the c-Jun and collagenase promoter, containing a single TRE-binding site, JunB is
not. In fact, JunB can inhibit the activation of these promoters. However, JunB can activate constructs
containing multiple TREs (Chiu et al., 1989). c-Jun and JunB have been to shown to act antagonistically
in controlling cell transformation, differentiation and expression of AP-1-dependent target genes. In rat
embryonal fibroblasts JunB can induce transformation when coexpressed with activated c-Ha-ras, but
it is significantly less active than c-Jun. When c-Jun and JunB are cotransfected c-Ha-ras-induced
transformation is markedly inhibited, if compared to c-Jun alone (Schutte et al., 1989).
JunD
The third member of the jun-family, junD, was cloned shortly after the discovery of junB (Ryder et al.,
1989). JunD has similar primary structure, DNA-binding and phosphorylation sites as c-Jun. JunD is
the most ubiquitously expressed of the AP-1 proteins (Hirai et al., 1989; Ryder et al., 1989). Opposing
roles for c-Jun and JunD have been proposed in cell cycle regulation and cell proliferation. However,
JunD-deficient fibroblasts also have reduced proliferation, indicating that JunD regulates cell cycle
progression both positively and negatively depending on the cellular context (Weitzman et al., 2000;
Meixner et al., 2004). In contrast to c-Jun, overexpression of JunD in fibroblasts suppresses proliferation
and antagonizes Ras-mediated transformation (Pfarr et al., 1994). JunD has been shown to directly
interact with menin, the product of the tumor suppressor gene MEN1. Menin interaction inhibits the
transcriptional activity of JunD by inhibiting both ERK- and JNK-dependent phosphorylation of JunD
(Gallo et al., 2002). In addition, JunD expression is increased during osteoblast differentiation, but
menin suppresses osteoblast maturation possibly by inhibiting the differentiation actions of JunD (Naito
et al., 2005). JunB and JunD knock-out data will be discussed later and is summarized in Table 2.
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3.4. c-Fos
An important step in defining the AP-1 transcription factor came with the discovery that the viral
oncoprotein c-Fos binds to the same DNA sequence as c-Jun (Rauscher et al., 1988). c-Fos was originally
identified in the FBJ (Finkel, Biskis, Jinkins) and FBR (Finkel, Biskis, Reilly) murine sarcoma viruses
(Curran et al., 1982). c-fos is an immediate-early proto-oncogene with rapid and transient transcriptional
activation following mitogenic stimuli (Greenberg and Ziff, 1984). Like c-Jun, c-Fos is involved in
numerous cellular processes such as proliferation, differentiation, transformation, and apoptosis.
3.4.1. Structure of c-Fos
The 4 kb mammalian c-fos gene has four exons and transcribes a 2.2 kb mRNA. c-Fos protein is
composed of 381 amino acids (reviewed by Piechaczyk and Blanchard, 1994). Similar to Jun proteins,
all Fos proteins share a hydrophobic bZIP that mediates protein-protein interactions, and a basic region
that mediates DNA binding. Fos family members are able to form heterodimers with Jun proteins, with
varying affinities (Hai and Curran, 1991). c-Fos also contains a more recently discovered ERK-docking
site, the DEF domain, in the C-terminus (Figure 4) (Murphy et al., 2002). c-Fos mRNA and protein are
very unstable. c-Fos is degraded by ubiquitination, but also by ubiquitin-independent mechanisms through
two distinct regions in the C- and N-terminus, called destabilizers. The C-terminal destabilizer of c-Fos
does not need an active ubiquitin cycle, whereas the N-terminal destabilizer is dependent on ubiquitination.
In asynchronous cells, c-Fos destruction is controlled by the C-terminal destabilizer, whereas in G
0
/G
1
cells c-Fos is degraded both by C- and N-terminal destabilizers (Bossis et al., 2003).
3.4.2. Expression of c-Fos
c-Fos protein is expressed at low or undetectable levels in most cell types, but is rapidly and transiently
induced in response to various stimuli, such as growth factors, and environmental and physical stress.
c-Fos is associated with a variety of biological processes, from cell-cycle progression and cell
differentiation to cell transformation and tumorigenesis (Shaulian and Karin, 2001). High levels of c-
Fos can be found in developing bone, the central nervous system, and in some hematopoietic cells, such
as megakaryocytes (Dony and Gruss, 1987; Caubet et al., 1989; Alitalo et al., 1990; Smeyne et al.,
1992). Tumorigenic properties of c-Fos have been demonstrated by overexpression, which causes
osteosarcomas by transforming chondroblasts and osteoclasts (Grigoriadis et al., 1993).
3.4.3. Activation and regulation of c-Fos
Like Jun proteins, Fos proteins must dimerize upon activation. Fos proteins cannot form homodimers,
but can heterodimerize with Jun proteins (Halazonetis et al., 1988). Fos proteins can interact with
other bZIP transcription factors such as the maf proto-oncogens (Kataoka et al., 1996). In addition, c-
Fos has been shown to interact with several other regulators of transcription, such as the co-activator
CBP and the GATA-4 transcription factor (Bannister and Kouzarides, 1995; McBride et al., 2003).
The regulation of c-Fos has mostly been studied at the level of mRNA. The activity of the c-fos promoter
is modulated by numerous extracellular signals, which act through several cis-inducible elements. A cis-
inducible enhancer (SIE) is regulated by STAT transcription factors, which are regulated by ERKs
(Wyke et al., 1996). Serum-response element (SRE) is another cis element regulating c-fos, by binding
to  serum-response  factor  (SRF),  which  recruits  ternary complex factors (TCFs). Activated ERK can
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phosphorylate this complex and stimulate its transactivating capacity, resulting in the activation of c-fos
(Gille et al., 1992). After translation c-Fos is phosphorylated at the N-terminus at threonine 232, the
homologue of serine 73 of c-Jun, by a Ras-responsive threonine kinase related to MAPKs (Deng and
Karin, 1994). This phosphorylation is involved in the activation of the transactivation potential of c-
Fos. c-Fos has also been shown to be phosphorylated by ribosomal S6 kinase (RSK) at serine 362 and
by ERKs at threonines 325 and 331, and serine 374 in the C-terminus after serum and PDGF stimulation
(Chen et al., 1996; Monje et al., 2003). p38 MAPKs phosphorylate c-Fos in response to UV treatment.
This phosphorylation occurs at threonines 232, 325 and 331 and at serine 374. None of the serines
appear to be sufficient for transcriptional activation by themselves and more than one is required for
maximal phosphorylation and transcriptional activation (Tanos et al., 2005).
In addition to the TCF-SRF complex, the cyclic AMP response element-binding protein (CREB) binds
to three separate sequences within the c-fos promoter. During NGF induction, activated ERK and p38
MAPKs stimulate CREB phosphorylation at a regulatory site. Once phosphorylated, CREB stimulates
c-fos transcription possibly by collaborating with SRE factors SRF and TCF (Xing et al., 1998).
c-Fos can together with c-Jun induce transcription of cytokine genes by interacting with nuclear factor
of T cells (NFAT) proteins (Chen et al., 1998; Macian et al., 2000). Binding of AP-1 cooperatively with
NFAT proteins improve the DNA-binding and transcriptional activity induced by AP-1 or NFAT proteins
alone. TGFβ-induced transcription is mediated by c-Jun/c-Fos together with Smad3 and Smad4 through
physical and functional interactions. Smads can mediate TGFβ-induced transcription without c-Jun and
c-Fos, but they bind to accessible AP-1 proteins mainly through Smad3-c-Jun interaction. This
multiprotein complex is more stable and transcriptionally more active (Zhang et al., 1998).
AP-1 family members are nuclear proteins bound to DNA constitutively in many conditions, whereas
many of their interaction partners are localized in the cytosol, and have to translocate to the nucleus
prior to AP-1 interaction. Casein kinase 2-interacting protein-1 (CKIP-1) functions as a plasma membrane-
bound protein that regulates AP-1 activity. During apoptosis CKIP-1 is cleaved through caspase-3-
dependent mechanisms, and translocated to the nucleus. Apoptosis promoted by CKIP-1 forms a positive
feedback loop with caspase-3. The C-terminal cleaved fragments reduce AP-1 activity and favor apoptosis
through enhanced caspase-3 activity (Zhang et al., 2005).
3.5. Other Fos proteins
FosB
Fos-oncoproteins include several family members in addition to c-Fos; FosB, Fra-1, and Fra-2 (Zerial
et al., 1989; Matsui et al., 1990). FosB expression is induced like c-Fos in response to serum and
mitogens. FosB forms a complex with c-Jun and JunB in vitro (Zerial et al., 1989). The expression of
FosB has been localized to neuronal tissue and bone during embryonic development, although no
known essential function during embryonic development has been identified (Gruda et al., 1996). FosB-
deficient mice develop normally but have a nurturing defect (Brown et al., 1996).
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Fra-1 and Fra-2
Another Fos-family member, fos related antigen-1 (Fra-1), lacks the C-terminal transactivation domain
and has therefore been proposed to be a negative regulator of AP-1 activity. Overexpression of fra-1
has a growth inhibitory effect and induces apoptosis in glioma cells (Shirsat and Shaikh, 2003). On the
contrary, Fra-1 is involved in Ras-induced transformation of NIH 3T3 cells, and it stimulates
transformation, and increases invasiveness and motility of epithelioid adenocarcinoma cells, reflecting
cases where Fra-1 does not act as a negative regulator of AP-1 (Mechta et al., 1997; Kustikova et al.,
1998). fra-2 has a peculiar expression pattern compared to those observed in other fos-related genes,
suggesting that fra-2 has a unique role in cellular differentiation during fetal development. Fra-2 expression
has been identified in differentiating epithelia, developing cartilage and in the central nervous system
during embryonic development (Carrasco and Bravo, 1995). Fos knock-out mice will be discussed
later and are summarized in Table 2.
3.6. Putative AP-1 target genes
The TRE element was first identified in the promoters of the simian virus 40 (SV40) enhancer, and of
the metallothionein and collagenase genes (Angel et al., 1987b; Lee et al., 1987). Transcription of these
genes is activated by TPA, and requires AP-1 activity. Consequently collagenase and metallothionein
genes are regarded as target genes of AP-1. Many genes have been found to have AP-1 binding sites in
their promoter regions, and could be considered as target genes. In general, Jun proteins regulate genes
involved in cellular proliferation and apoptosis, whereas the putative target genes of Fos proteins are
often associated with angiogenesis and tumor invasion. However, the target genes of AP-1 are to date
poorly characterized. Recently, it has been shown that dimer composition of AP-1 plays a role in the
regulation of AP-1 targets. Binding of c-Jun/c-Fos dimers activates the collagenase promoter more
effectively than binding of c-Jun/Fra-2 or c-Jun/ATF-2 dimers (Bakiri et al., 2002).
In an in vitro skin model, c-Jun promotes, whereas JunB suppresses, the expression of keratinocyte
growth factor (KGF) and granulocyte/macrophage colony-stimulating factor (GM-CFS), affecting
keratinocyte proliferation and differentiation (Szabowski et al., 2000). Cell cycle progression is also
regulated by Jun proteins, as c-Jun activates transcription of cyclin D1, a cell cycle promoting gene, and
represses cell cycle inhibiting genes p53 and INK4A (Schreiber et al., 1999; Bakiri et al., 2000; Passegue
and Wagner, 2000). Matrix metalloproteinases (MMPs) are necessary during cell invasion when the
extracellular matrix is degraded. Metalloproteinases stromelysin (MMP-3) and type I collagenase (MMP-
1), are regulated by c-Fos and Fra-1 (Hu et al., 1994). In addition, Fra-1 directly induces MMP-1 and
MMP-9 promoter activities in breast cancer cell lines (Belguise et al., 2005). MMP9 has been reported
to be regulated by AP-1 during in vitro invasion of cancer cells (Simon et al., 2001). The nerve growth
factor (ngf) gene has been suggested to be regulated by c-Fos (Hengerer et al., 1990), and HMG-I/Y
chromatin binding protein has been suggested to be a direct transcriptional target of c-Jun, being necessary
for c-Jun-induced anchorage-independent growth in fibroblasts (Hommura et al., 2004)
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4. AP-1 during cell growth, differentiation, and organ development
As mentioned above, AP-1 is known to have a role in cell proliferation. c-Jun is a positive regulator of
cell proliferation, indicated by fibroblasts from c-jun-/- mice having a proliferation defect due to defective
cell cycle progression and undergoing premature senescence (Johnson et al., 1993; Wisdom et al.,
1999). Moreover, c-Jun deficiency leads to enhanced expression of tumor suppressor p53 and its target
p21. p21 is an inhibitor of many cyclin-dependent kinases in the cell cycle, and upregulation of p21
results in disturbed S-phase entry (Schreiber et al., 1999). In addition, cyclin D1 expression is reduced
in c-Jun-deficient fibroblasts leading to impaired cell proliferation (Wisdom et al., 1999; Bakiri et al.,
2000). The dimer composition of AP-1 is important during the regulation of the cell cycle. c-Jun/Fra-1
dimers cooperate with Ras leading to growth arrest by upregulating the tumor suppressor gene p19ARF
in fibroblasts. p19ARF regulates the p53 pathway, and consequently AP-1 provides a link between
oncogenic Ras and p53 (Ameyar-Zazoua et al., 2005).
The role of AP-1 in differentiation is established by knock-out studies and the phenotypes of Jun and
Fos knock-out animals are presented in Table 2. c-Jun knock-out studies implicate an essential role for
c-Jun in mouse embryonal development (Johnson et al., 1993). c-jun-/- embryos die embryonally at
mid-to-late gestation due to massive liver hemorrhage and extensive apoptosis in both hematopoietic
cells and hepatoblasts (Hilberg et al., 1993; Eferl et al., 1999). A similar phenotype is observed in
mkk4-/- embryos (Ganiatsas et al., 1998). In addition, c-Jun-deficient fetuses have malformations in the
outflow tract of the heart resembling the human disease of a truncus arteriosus persistens (Eferl et al.,
1999). c-jun-/- embryonic stem cells differentiate into germ and somatic cells, but not into hepatocytes,
suggesting an essential role for c-Jun in hepatogenesis. Recently, a role in the development of the axial
skeleton has been proposed. Absence of c-Jun results in increased apoptosis of notochordal cells and
impaired formation of the intervertebral disc (Behrens et al., 2003).
For a long time JunB was considered to be a negative regulator of transcription. More recently, it has
been shown that JunB is a strong transcriptional activator of IL-4 during T helper cell differentiation (Li
et al., 1999). For example, JunB suppresses cell proliferation by activating cyclin-dependent kinase
inhibitor INK4A, leading to premature senescence and reduced cell proliferation (Passegue and Wagner,
2000). JunB-deficient embryos die between E8.5 and E10.0 due to defects in the vasculature of extra
embryonic tissues (Schorpp-Kistner et al., 1999). The mutant placentas lack a vascularized labyrinth
layer and yolk sack vascularization is impaired. JunB appears to be necessary for hematopoietic
differentiation since transgenic mice lacking JunB in the myeloid lineage develop blast crisis, resembling
human chronic myeloid leukemia, supporting the role of junB as a tumor suppressor (Passegue et al.,
2001). Inactivation of junB postnatally at the stem cell level also leads to myeloproliferative disorder
(Passegue et al., 2004). Additionally, overexpression of JunB in B-lymphoid cells blocks proliferation
of the cells accompanied by increased expression of cyclin-dependent kinase inhibitor INK4A (Szremska
et al., 2003).
Consistent with the role of c-Jun as a positive and JunB as a negative regulator of cell proliferation is
the  antagonistic  effects  of  c-Jun  and  JunB  during  keratinocyte  differentiation.  c-jun  -/-  fibroblasts
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cultured together with keratinocytes induce proliferation of keratinocytes very poorly. In contrast,
when junB-/- fibroblasts are co-cultured with keratinocytes, keratinocytes become hyperproliferative.
The differences are due to keratinocyte growth factor (KGF) and granulocyte-macrophage colony-
stimulatory  factor  (GM-CSF),  which  are  suppressed  in c-jun -/- fibroblasts  and  overexpressed in
junB-/- fibroblasts (Szabowski et al., 2000). A recent study has also demonstrated the role of JunB in
osteoclast and osteoblast activity. Conditional JunB knock-out mice have reduced proliferation and a
differentiation defect in osteoclast precursors and osteoblasts. When JunB is deleted in the macrophage-
osteoclast lineage the mice develop an osteopetrosis-like phenotype with increased bone mass and a
reduced number of osteoclasts (Kenner et al., 2004).
Even though c-Jun and JunB have been shown to have antagonistic functions in many cell types in vitro,
a remarkable finding has been made by Passegue and co-workers (Passegue et al., 2002). The
transcriptionally less active JunB can substitute for c-Jun during mouse development. Introduction of
JunB into c-jun -/- mice rescues both liver and cardiac defects in a dose-dependent manner.
The effects of JunD on proliferation are more complex. Overexpression of JunD in fibroblasts slows
proliferation of the cells (Pfarr et al., 1994). Consistent with these results, immortalized junD-/- cells
show accelerated proliferation linked to higher cyclin D1 levels and are more sensitive to p53-dependent
apoptosis upon UV irradiation. In contrast, primary fibroblasts lacking JunD undergo p53-dependent
growth arrest and premature senescence (Weitzman et al., 2000). It has also been demonstrated that
JNK-stimulated cell survival can be mediated by JunD. In fibroblasts treated with TNF-α, the role of
JNK is mediated by JunD, which collaborates with NF-κB to increase the expression of survival genes
(Lamb et al., 2003). Additionally, JunD overexpression suppresses B and T lymphocyte proliferation
and T helper cell differentiation. T helper cell differentiation implies antagonistic functions for JunB and
JunD through cellular cytokines. JunB activates the expression of interleukin-4 (IL-4) and triggers
differentiation of T helper cells into Th2 cells, whereas JunD reduces IL-4 production and suppresses
Th2 differentiation (Hartenstein et al., 2002; Meixner et al., 2004).
During embryonic development, JunD expression is detected in the developing heart and cardiovascular
system, whereas in adults JunD expression is widespread in many tissues and cell lineages (Hirai et al.,
1989; Ryder et al., 1989). junD-/- mice are viable and appear healthy, although junD-deficient males
show age-dependent defects in reproduction, hormonal imbalance and impaired spermatogenesis (Thepot
et al., 2000). In addition, a well-balanced expression of junD has been suggested to be crucial for heart
function. Mice lacking junD develop cardiac hypertrophy after mechanical pressure overload, whereas
overexpression of junD in the heart leads to ventricular dilation and reduced contractility (Ricci et al.,
2005).
The roles of Fos proteins in development and differentiation seem to be dispensable.  Mice lacking c-
Fos are viable but suffer from an osteopetrotic phenotype due to the lack of osteoclasts, the resorbing
type of bone cells (Johnson et al., 1992). Furthermore, c-fos-/- mice have abnormalities in the
hematopoietic system (Wang et al., 1992). ATF-2-deficient mice have a similar phenotype to c-Fos
knock-out mice, with defects in bone formation (Johnson et al., 1992; Reimold et al., 1996).
Overexpression  of  c-Fos  in  ES  cells  and in transgenic mice results in oncogenic transformation and
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development of chondrosarcomas and osteosarcomas (Wang et al., 1991; Grigoriadis et al., 1993). c-
Fos/p53 double knock-out mice develop highly proliferative and invasive rhabdomyosarcomas
(Fleischmann et al., 2003). Knock-out mice of another Fos family member, FosB, develop normally,
but adult females have a nurturing defect (Brown et al., 1996). This correlates well with the lack of
FosB in a hypothalamic region which is critical for nurturing behaviour.  fra-1-/- mutant mice die
embryonally due to placental and yolk sac defects (Schreiber et al., 2000). The labyrinth layer of mutant
placentas is smaller than in wild types and lacks vascularization.  fra-2-/- mice have yet not been
reported, but overexpression of Fra-2 leads to malformations of the eye due to developmental defects
in anterior eye structures (McHenry et al., 1998).
Table 2.  Phenotypes of AP-1 knock-out animals
5. The role of AP-1 in apoptosis
Apoptosis is the process where cells and organelles that are useless or potentially dangerous, such as
aged, injured or mutated cells, are eliminated. Many transcription factors and proteins involved in cell
growth are also important during apoptosis. The role of AP-1 in cell fate depends on the cellular
context, resulting in different and sometimes even opposite responses. The inconsistency of AP-1 in
apoptosis is best illustrated by the role of c-Jun in neuronal cells and hepatocytes. Neutralizing antibodies
or a dominant negative mutant of c-Jun protect sympathetic neurons against apoptosis induced by
NGF-withdrawal, and overexpression of c-Jun induces apoptosis in sympathetic neurons and fibroblasts
(Estus et al., 1994; Ham et al., 1995; Bossy-Wetzel et al., 1997). c-Jun is also activated in neuronal
injury, and is required for axonal regeneration (Raivich et al., 2004). c-Jun mutants in which the MAPK
phosphorylation sites have been mutated into non-phosphorylated alanines have defects in proliferation
and in stress-induced apoptosis (Behrens et al., 1999). These mutants are resistant to kainite-induced
neuronal apoptosis. On the contrary, c-Jun prevents apoptosis during mouse hepatogenesis  (Hilberg  et
al.,  1993; Behrens  et  al., 1999; Eferl et al., 1999) and  primary  embryonic fibroblasts lacking c-Jun
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Disrupted gene Phenotype Affected organ/ cell type References
c-Jun Embryonic lethal (E12.5) Liver, heart outflow tract (Hilberg et al. , 1993; Johnson
et al. , 1993; Eferl et al. , 1999)
JunB Embryonic lethal (E8.5-10) Extra-embryonic tissue, 
placenta, yolk sac
(Schorpp-Kistner et al. , 1999)
JunD Male sterility,               
cardiac hypertrophy
Testis, heart (Thepot et al. , 2000; Ricci et
al. , 2005)
c-Fos Osteopetrosis Bone, osteoclasts (Johnson et al. , 1992; Wang
et al. , 1992)
FosB Nurturing defect Brain, hypothalamus (Brown et al. , 1996)
Fra-1 Embryonic lethal (E9.5) Extra-embryonic tissue, 
placenta, yolk sac
(Schreiber et al. , 2000)
Fra-2 Not characterized
ATF-2 50% survival Hypochondroplasia,     
central nervous system
(Reimold et al. , 1996)
are more sensitive to UV-induced apoptosis (Wisdom et al., 1999). JunD protects cells from Ras-
induced, p53-dependent senescence and apoptosis (Weitzman et al., 2000). However, apoptosis is not
always mediated through MAPK. For example, c-Jun activation during DNA damage-induced neuronal
apoptosis is JNK-independent (Besirli and Johnson, 2003).
There are many indications for c-Fos being a positive regulator of apoptosis during development, tissue
remodeling and in response to stress stimuli. In mice constitutively expressing fos-lacZ gene, reporter
c-Fos expression is observed in cells undergoing terminal differentiation and naturally occurring apoptosis
(Smeyne et al., 1992). Overexpression of c-Fos induces apoptosis in immature lymphocytes and in a
myeloid leukemia cell line, as well as in hepatocytes (Hu et al., 1996; Mikula et al., 2003). However, c-
Fos is not essential for apoptosis, since apoptosis also occurs in c-fos deficient mice (Roffler-Tarlov et
al., 1996).
Fra-1 and Fra-2 proteins have also been linked to apoptosis. Fra-1 overexpression induces apoptosis in
glioma and adenocarcinoma cells, and reduces cell growth and tumorigenecity (Kustikova et al., 1998;
Shirsat and Shaikh, 2003). Fra-2 levels are elevated in various forms of brain injury, suggesting that
Fra-2 may regulate genes involved in regeneration and repair of the central nervous system (Pennypacker
et al., 2000).
6.  AP-1 and tumorigenesis
Tumorigenesis is a process involving cell transformation, invasive growth, angiogenesis, and metastasis.
c-Jun controls transformation of chick embryo fibroblasts by two distinct genetic programs depending
on the dimerization partner. When c-Jun dimerizes with Fos proteins it induces anchorage-independent
growth, but not growth factor-independence. When dimerized with ATF2, c-Jun causes growth factor-
independence, but not cell growth in soft agar, suggesting that c-Jun regulates different sets of genes
depending on its dimerization partners (van Dam et al., 1998). c-Jun overexpression enhances the
tumorgenic properties of human mammary carcinoma cell line MCF7, inducing elevated motility,
increased tumor formation in nude mice and unresponsiveness to estrogen or tamoxifen (Smith et al.,
1999). c-Jun overexpression induces the expression of the secreted protein acidic and rich in cysteine
(SPARC)/osteonectin gene, stimulating motility and invasive behavior of the cells (Briggs et al., 2002).
SPARC may contribute to motility and invasion through MMP activation (Gilles et al., 1998). c-Jun
induces transformation of primary rat embryo fibroblasts when expressed together with constitutively-
active Ras (Behrens et al., 2000). However, together with c-Fos, c-Jun overexpression leads to formation
of skeletal osteosarcomas (Wang et al., 1995). c-Fos has oncogenic activity which depends on its
ability to heterodimerize with Jun-proteins and bind to DNA. c-Fos overexpression transforms
chondoroblasts and osteoblasts (Ruther et al., 1989; Grigoriadis et al., 1993). FosB also has transforming
potential as it transforms fibroblasts in cell culture conditions (Kovary et al., 1991; Schuermann et al.,
1991), whereas the transforming and oncogenic activity of Fra-2 is weak compared to other Fos-
proteins. Fra-1 is constitutively expressed in more aggressive breast tumor cell lines and induces
transformation, motility, and invasiveness of adenocarsinoma and breast cancer cells (Kustikova et al.,
1998; Belguise et al., 2005). Fra-1 is also expressed in aggressive breast carcinomas in vivo (Zajchowski
et al., 2001).  More recently, Fra-2 has been suggested to be involved in invasion of breast cancer cells
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together with Fra-1 and c-Fos (Milde-Langosch et al., 2004). Unlike c-Jun, both JunB and JunD were
earlier thought to lack transforming activity and to inhibit oncogenic transformation by Ras, thereby
acting as anti-oncogens (Schutte et al., 1989; Pfarr et al., 1994; Passegue and Wagner, 2000). The role
of JunB as a tumor suppressor is further supported by the development of chronic myeloid leukemia in
mice lacking JunB in the myeloid lineage (Passegue et al., 2001). JunB also inhibits proliferation and
transformation in B-lymphoid cells (Szremska et al., 2003). However, JunB can rescue proliferation
defects caused by loss of c-Jun during mouse development, indicating that JunB can promote cell
growth in the absence of c-Jun (Passegue et al., 2002). JunD can switch from a growth suppressor to
growth promoter through interaction with the tumor suppressor protein menin. In normal conditions,
menin binds to JunD, inhibiting its transcriptional activity, but when JunD-menin binding was inhibited
by a JunD mutant unable to bind to menin or by using menin deprived cells, JunD changed from a
growth suppressor to a growth promoter (Agarwal et al., 2003). JunD protects cells from oxidative
stress by reducing production of reactive oxygen species and hypoxia-inducible factor 1α (HIF-1α)
stability, and reduces tumor angiogenesis in Ras-transformed fibroblasts (Gerald et al., 2004).
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AIMS OF THE STUDY
The main purpose of this research was to study the cellular mechanisms converting extracellular signals
into changes in gene expression. Mitogen-activated protein kinases (MAPKs) are important signal
transducers transmitting extracellular signals from the cell surface receptors into the nucleus, where
transcription factors modify gene expression, and consequently cell fate. AP-1 transcription factor is
regulated by MAPKs and since it is activated during cell proliferation, differentiation, and apoptosis, it
is important to clarify which cellular responses are regulated by AP-1 and how the signal is mediated.
The specific aims of this study were:
1. To study the possible activation of ERK, JNK, p38 MAPKs, and AP-1 in cell culture models of
cardiomyocyte, neuronal, and megakaryocytic differentiation.
2. To analyze the differences in AP-1 activation in response to ERK, JNK, and p38 signaling during
cellular differentiation and stress response.
3. To characterize the functions of c-Jun and c-Fos during neuronal differentiation and apoptosis.
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MATERIALS AND METHODS
1. Cell culture and treatments
All cells were cultured in a humidified 5% CO
2
 atmosphere at 37°C.
P19 cells
Mouse P19 embryonal carcinoma cells were cultured in Dulbecco´s modified Eagle´s medium containing
15% heat-inactivated fetal calf serum (Gibco), non-essential amino acids (Invitrogen), 1 mM pyruvate
(Invitrogen), 5x10-5 M β-mercaptoethanol, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml
streptomycin. Differentiation was initiated by growing 105 cells/ml on bacterial-grade plastic dishes in
the presence of 1% dimethyl sulfoxide (DMSO) (Sigma). On day 4 the cells were plated on tissue
culture-grade dishes, and the differentiation of cells was continued in media without DMSO.
K562 cells
Human K562 leukemia cells were maintained in RPMI 1640 medium containing 10% heat-inactivated
fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Differentiation
toward megakaryocytic and erythroid lineages was induced by 10 mM 12-O-tetradecanoylphorbol 13-
acetate (TPA, Sigma) or 30 µM hemin (Sigma), respectively.
PC12 cells
Rat phechromocytoma PC12 cells were cultured on collagen-coated plates in Dulbecco’s modified
Eagle´s medium supplemented with 10% heat-inactivated horse serum and 5% fetal calf serum (Gibco),
2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.  Neuronal differentiation of
PC12 cells was induced by adding nerve growth factor (NGF, 50 ng/ml, Sigma) to cells, which were
first incubated in medium containing 0.5% horse serum for 16 hours. Anisomycin (50 ng/ml or 10 µg/
ml, Sigma) was added to induce the stress-activated MAPK pathways.
293 cells
Human embryonic kidney 293 cells were cultured in Dulbecco’s modified Eagle’s medium with 10%
heat-inactivated fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.
MAPK-inhibitor treatments
MEK (PD98059), JNK (SP600125) and p38 (SB203580) inhibitors (Calbiochem) diluted in DMSO
were added 1 hour prior to DMSO, TPA, NGF, or anisomycin, treatments at  20 µM, 10 µM, and 10
µM, respectively. For long incubations fresh medium containing inhibitors was changed every 24 hours.
Analysis of cell proliferation and apoptosis
For cell proliferation assays, P19 cells were plated onto 96-well plates at a density of 1500 cells/well in
triplicates and cultured for 1 to 6 days. PC12 cells were plated onto collagen-coated 12-well plates in
duplicates at a density of 20 000 cells/well. On days 1, 3 and 6 cells were fixed with 2% paraformaldehyde
(PFA) for 1 hour on ice, stained with crystal violet (0.5% in ethanol), and washed with distilled water.
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Stained cells were dissolved in 10% acetic acid, and the cell number assessed spectrophotometrically
by absorbance at 560 nm (Multiscan, Labsystems).
For differentiation and apoptosis studies PC12 cells were transfected with MAPK, AP-1 and  ATF-2
mutants together with nuclear β-galactosidase using Fugene6 reagent (Roche) (see Table 3).
To characterize apoptotic cells, PC12 cell nuclei were stained using TUNEL (terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling). The staining was performed
according to the manufacturer’s instructions (Roche). Apoptotic nuclei were also detected by Hoechst
stain. The morphological changes characteristic for apoptosis, including disruption of the nuclear
membranes and nucleus, were scored with a Axiovert 200 fluorescence microscope (Zeiss).
2. Expression analyses
Microinjections
For microinjections, PC12 cells were seeded onto laminin-coated plastic dishes (20 µg/ml mouse laminin,
Sigma) to provide better adhesion and to facilitate neurite outgrowth. Microinjections were performed
by an automated injection system and an inverted microscope (Zeiss). All plasmids were injected into
the nucleus of the cells at a concentration of 50 µg/ml of expression vector. A total of 100-150 cells
were injected per experiment.
Transfections and reporter gene analysis
For reporter analyses, duplicates of 60-mm diameter plates containing 105 P19, K562, or PC12 cells
were transfected using the Fugene6 reagent. The internal control Renilla-luc and the reporter constructs
AP-1-luc and col luc were used (see Table 3). 24 hours after transfection the cells were collected and a
Dual-Luciferase assay performed according to the manufacturer’s instructions (Promega). The activities
of the reporters were normalized to the activity of Renilla luciferase.
For expression studies, K562 cells were transfected with the indicated plasmids (see Table 3) together
with EGFP-spectrin using the Lipofectamine 2000 transfection system (Invitrogen) according to the
manufaturer´s instructions. The following day, transfected cells were split and TPA (10 nM) was added
to half of the cells. After 48 hours, the cells were collected for further analysis.
For stable cell clones, P19 cells were transfected with plasmids encoding a HA-tagged c-JunbZIP and a
neomycin resistance gene (pCIneo) using the Fugene6 reagent. After 48 hours, Geneticin (G418 1 mg/
ml, Sigma) was added to cells for selection of stable clones. An expression plasmid for Flag-tagged
JNKAPF plasmid was transfected together with a puromycin resistance gene (pBabe Puro) and the selection
of positive cell clones was carried out in the presence of 1-2 µg/ml Puromycin (Sigma). An expression
vector for SEKAL carried a Zeocin resistance gene and the positive clones were selected with 250-300
µg/ml Zeocin (Invitrogen). The cell clones expressing c-JunbZIP, JNKAPF, and SEKAL were screened by
immunostaining for HA-, Flag-epitope, or SEK1, respectively.
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For c-Jun phosphorylation studies, 293 cells were transfected with wild type c-Jun and c-Jun∆31-57 alone
or together with ∆MEKK with Fugene6 reagent. Cells were harvested 24 hours after transfection.
Table 3. Plasmids used in this study
siRNA analyses
For small interfering RNA (siRNA) studies, K562 cells were transfected with an empty vector pMT14
or c-fos siRNA (100 nm, Dharmacon RNA Technologies) together with EGFP Spectrin using the
lipofectamin 2000 transfection system according to the manufacturer’s instructions. The following day
cells were split and TPA (10 nM) was added to half of the cells. After 48 hours the cells were collected
for further analyses.
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Plasmid Reference Used in study
AP-1 Luc Clontech II
ATF-2 provided by P. Angel IV
ATF-2
AA provided by P. Angel IV
ATF-2
ED provided by P. Angel IV
c-Fos (Curran et al. , 1982) II, IV
c-Jun
ALA (Treier et al. , 1995) IV
c-Jun
ASP (Treier et al. , 1995) IV
c-Jun
bZIP (Leppä et al. , 1998) I, II, IV
c-Jun
WT (Treier et al. , 1995) I, II, IV
c-Jun∆31-57 (Treier et al. , 1994) IV
c-Jun
1-22NLS (Treier et al. , 1994) IV
c-Jun
MUT12 this study IV
c-Jun
MUT14 this study IV
c-Jun
MUT17 this study IV
c-Jun
MUT22-23 this study IV
col luc (Treier et al. , 1995) IV
EGFP spectrin (Kalejta et al. , 1997) II, III
ERK2/MEK1 (Robinson et al. , 1998) II
JNK
APF (Derijard et al. , 1994) I
JunB provided by M. Yaniv IV
JunD provided by M. Yaniv II, IV
JunD
ASP provided by A.M. Musti II
MEK1 (Cowley et al. , 1994) III
MEKK1 (Whitmarsh et al. , 1995) II, IV
MKK1 (Mansour et al. , 1994) I
MKK4 provided by J. Woodgett I
MKK6 (Alonso et al. , 2000) I
nuclear β-galactosidase (Treier et al. , 1994) IV
pBabe Puro (Morgenstern and Land, 1990) I
pCIneo Promega I
pJC6luc (Clarke et al. , 1998) I
pJSXluc (Clarke et al. , 1998) I
pJTXluc (Clarke et al. , 1998) I
Renilla-luc provided by C. Weiss I, II, IV
SEK
AL (Yan et al. , 1994) I
For PC12 cell siRNA studies, cells were seeded on laminin-coated dishes (20 µg/ml mouse laminin,
Sigma) for better attachment and to help neurite outgrowth. Mouse/rat c-fos siRNA duplexes
(CUGAGAAGACUGGAUAGAG),       (CCCUUUGAUGACUUCUUGU),       (UACCUACUGUG
UUCCUGGC) were chemically synthesized (Proligo). c-fos siRNA and/or constitutively active MEK1
(Cowley et al., 1994) was transfected together with EGFP Spectrin, with Lipofectamin 2000 transfection
reagent according to manufacturer’s instructions. 24 hours after transfection the siRNA-transfected
cells were incubated in media containing 0.5% horse serum for 16 hours. NGF (50 ng/ml) was added to
the cells and 30-36 hours later the cells were fixed with 2% PFA. The cells transfected with constitutively
active MEK1 and c-fos siRNA were fixed in 2% PFA 48 hours after transfection. To confirm the
downregulation of c-Fos, the transfected cells were treated with 0.1 µM TPA for 1 hour, and fixed with
2% PFA.
3. RNA analyses
 Real-time quantitative PCR
Integrin α
2
 mRNA levels in K562 cells were determined by quantitative PCR, using Integrin alpha RT2
Real-TimeTM Gene Expression Assay Kit (Super Array), and the Gene Amp 5700 Sequence Detection
System (Applied Biosystems) according to the manufacturer’s instructions. Template cDNA was prepared
from total cellular RNA using ReactionReadyTM First Strand cDNA Synthesis Kit (SuperArray). All
reactions were repeated in duplicates and the gene expression levels were normalized to GAPDH levels
within the same experiment.
Northern analysis
Total cellular RNA was isolated using the single step method (Chomczynski and Sacchi, 1987). 10-20
µg of RNA was separated on a 1% agarose-formaldehyde gel and transferred to nylon membrane
(Hybond-N, Amersham). Filters were hybridized with [α-32P]dCTP-labeled cDNAs coding for mouse
c-jun, junD, PDGF-A, GAPDH, and ribosomal 18S (Ambion). Hybridizations and washing were
performed using standard procedures (Sambrook et al., 1989).
4. Electrophoretic mobility shift assay (EMSA)
Cells were harvested by centrifugation and quick freezing in liquid nitrogen. Cell pellets were homogenized
in two volumes of buffer containing 20 mM Hepes pH 7.9, 0.42 M NaCl, 25% (v/v) glycerol, 1.5 mM
MgCl
2
, 0.2 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF),
10 µg/ml aprotinin, 2.5 µM leupeptin, 25 mM β-glycerophosphate and 0.1 mM Na
3
VO
4
. Amounts of
total soluble protein were measured with the BCA Protein Assay Kit (Pierce). For nuclear extracts,
cells were lysed in buffer containing 10 mM HEPES, pH7.9, 1.5 mM MgCl
2
, 10 mM DTT, 0.5 mM
PMSF, 10 µg/ml aprotinin, 2.5 µM leupeptin, 25 mM β-glycerophosphate, and 0.1 mM Na
3
VO
4
.
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EMSA probes with consensus AP-1 site 5’-GATCTATCTGAGTCAGCAG-3’, consenus HSE site 5’-
GTCGACGGATCCGAGCGCGCCTCGAATGTTCTAGAAAAGG-3’, and α2-integrin enhancer 5’-
AAACACTTACTCACATTTCAGTGAGTC-3’ were 5’-end labelled with [γ-32P]ATP using High Prime
(Promega). The labelled sense oligos were annealed with antisense oligos.
To assay DNA-binding activity, cell or nuclear extracts were incubated for 20 minutes at room temperature
in a reaction buffer containing 10 mM Tris (pH 7.5), 50 mM NaCl, 1mM EDTA, 5% (v/v) glycerol, 0.5
mM DTT, 0.5 mM PMSF, 40 µg/ml poly (dI-dC) (Amersham Pharmacia Biotech), 400 µg/ml bovine
serum albumin (BSA), and 0.1 ng 32P-labeled oligonucleotide probe. Protein-DNA complexes were
resolved on 4% nondenaturating polyacrylamide gels containing 0.5xTBE (5,58 mM Tris-borate, 0,125
mM EDTA) and visualized by autoradiography.
For antibody perturbation assays, 1 µg of immunosera specific for c-Jun, JunB, JunD, c-Fos, FosB,
Fra-1, Fra-2, and ATF-2 (Santa Cruz) were preincubated with the cell extracts for 15 minutes at room
temperature prior to assays for DNA-binding activity.
5. Protein analyses
Flow cytometric analysis
K562 cells were harvested, washed three times with phosphate buffered saline (PBS), and incubated for
1hour at room temperature with primary antibodies described in Table 4. Subsequently, cells were
washed and incubated for 1 hour at room temperature with phycoerythrin-conjugated donkey anti-
mouse antibody (Jackson Immunoresearch). After three washes cells were resuspended in PBS and
analyzed immediately by FACSCalibur (Becton Dickinson).
Western analysis
Whole-cell extracts were prepared as described above. Alternatively, cells were collected directly into
sodium dodecyl sulfate (SDS) buffer and sonicated with a MSE Soniprep 150 sonifier. Proteins (30-
200 µg) were separated on 10% SDS-polyacrylamide gels followed by electroblotting onto nitrocellulose
membranes (BioRad). Immunoblotting was performed using primary antibodies described in Table 4.
HRP-conjugated secondary antibodies were purchased from the Jackson laboratories. Blots were
developed with an enhanced chemiluminescence (Super Signal, Pierce).
In vitro kinase assays
Cells were washed with PBS and solubilized in lysis buffer containing 25 mM HEPES-NaOH pH 7.5,
150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA, 5 mM EGTA, 25 mM β-glycerophosphate,
and 0.1 mM Na
3
VO
4
. JNK was immunoprecipitated using polyclonal anti-JNK antibody (SantaCrutz)
for 1 hour at 4°C. Immunocomplexes were coupled to protein-A-Sepharose beads for 1 hour and
washed several times with dilution buffer (25 mM HEPES-NaOH pH 7.5, 5 mM EDTA, 5 mM EGTA,
25 mM β-glycerophosphate, 0.1 mM Na
3
VO
4
). Kinase reactions were performed with 2 µCi of [γ-
32P]ATP for 20 minutes at 30°C using GST-c-Jun protein (amino acids 5-105) as a substrate. The
phosphorylated  proteins  were  electrophoresed  on  a  10%  SDS-polyacrylamide gel and visualized by
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autoradiography. Alternatively 100 µM adenosine triphosphate (ATP) was added to kinase reactions
and the phosphorylated c-Jun proteins were immunoblotted using an antibody against c-Jun
phosphorylated at serine 73.
Table 4. Antibodies used in the studies
Methods used: Electrophoretic mobility shift assay (EMSA), flow cytometry (FC), immunocytochemistry (ICC),
immunohistochemistry (IHC), western blotting (WB).
Immunocytochemistry
Cells were fixed with 2% PFA in PBS, rinsed with PBS and permeabilized with 0.1% Triton-X in PBS
on ice. After blocking with 1% BSA for 30 minutes at room temperature, primary antibodies were
added to the cells and incubated for 1 hour at room temperature (see Table 4). After several washes
with PBS, the cells were incubated with a fluorescein isothiocyanate (FITC)-conjugated anti-mouse
antibody (Jackson Laboratories) together with tetranethyl rhodamine isothiocyanate (TRITC)-labelled
phalloidin (Sigma) to detect positive staining and cell morphology, respectively. After washes with
PBS, Hoechst dye 33258 (Sigma) was added to the last wash to visualize nuclei. Finally, the cells were
mounted under a coverslip using Mowiol. Samples were examined using a Zeiss LSM410 confocal
imaging system and Axiovert 200 fluorescence microscope (Zeiss). For quantification of neurite
outgrowth in PC12 cells, the cells forming neurite outgrowths longer than twice the diameter of the cell
body were scored as differentiated. The statistical significances of differences seen in cell survival and
neurite formation assays were analyzed using Student´s t tests. All P values were two tailed.
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Antibody Company Study  Method
β-galactosidase Promega IV IV, ICC
c-Fos Santa Crutz I, II,III WB, IHC, EMSA
c-Jun Cell Signaling Technologies I,II,III WB,EMSA
ERK1/2 Santa Crutz I,II,III WB
FVIII Chemicon II IHC
Fra-1 Santa Crutz I,II,III IHC, EMSA
Fra-2 Santa Crutz I,II,III WB, EMSA
Hsc70 StressGene I WB
HA-epitope, clone 12CA5 Roche I, IV ICC
integrin β3 (CD61) provided by I. Virtanen II FC
integrin α2β1 (CD49b) Serotech II FC
JNK1/2 Santa Crutz I,II,III WB
JunB Santa Crutz I,II WB, EMSA
JunD Santa Crutz I, II,III WB, IHC
MF-20 provided by M.Tiainen I WB
p38 Cell Signaling Technologies I,II,III WB
phospho-c-Jun Ser73 Cell Signaling Technologies I,II,III WB
phospho-ERK Promega I,II,III WB
phospho-JNK Promega III WB
phospho-p38 Cell Signaling Technologies I,II,III WB
Immunohistochemistry
For immunostainings, bone marrow biopsies were fixed in 4% PFA, embedded in paraffin and sectioned.
The sections were autoclaved in 0.1 M sodium citrate (pH 5.0) for 10 minutes and washed with PBS.
After blocking with normal horse serum for 30 minutes at room temperature, the sections were stained
with primary antibodies described in Table 4. Immunohistochemistry was completed using the Vectastain
ABC Kit reagents (Vector Laboratories) according to the manufacturer´s instructions. The
immunoreactions were visualized using 3-amino-9-ethylcarbazole AEC (0.2 mg/ml). After visualization,
the slides were counterstained with hematoxylin and mounted.
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RESULTS AND DISCUSSION
1. MAPKs and AP-1 are required for cardiomyocyte differentiation of P19 embryonal
carcinoma cells (I)
1.1. p38- and ERK-MAPKs regulate AP-1 activity during cardiomyocytic differentiation of P19 cells
c-Jun-deficient mice have a defect in heart outflow tract formation, which resembles persistent truncus
arteriosus (Eferl et al., 1999). Furthermore, hypertrophic growth of cardiac myocytes leads to AP-1
activation and consequently changes in gene expression of cardiac-specific genes (MacLellan and
Schneider, 2000). These findings prompted us to study MAPK and AP-1 function during
cardiomyogenesis. P19 embryonal carcinoma cells provide a useful model to study molecular mechanisms
during embryonic differentiation, since the cells can differentiate into various cell types from different
germinal layers. P19 cells are malignant, pluripotent teratocarcinoma stem cells, derived from the inner
mass of early mouse pre-implantation embryos (McBurney et al., 1982). Aggregation and DMSO
treatment differentiate P19 cells into beating cardiomyocytes. These rhythmically contracting cell
aggregates appear six days after induction of differentiation, at the time the expression of myogenic
markers is induced.
We observed that activation of JNK1/2, p38 and ERK1/2 MAPKs was induced during the P19 cell
differentiation response, followed by increased AP-1 DNA-binding activity and increased expression of
c-Jun, JunD, and Fra-2 AP-1 proteins. Consistent with the increased expression, the same proteins
were involved in the AP-1 DNA-binding complex induced during P19 cell differentiation into
cardiomyocytes. Parallel to the expression levels, the amounts of c-jun and junD mRNAs were
upregulated during DMSO-induced cardiomyocyte differentiation. The induction of the Fos-family
member Fra-2 was accompanied by decreased motility, most likely resulting from phosphorylation
(Murakami et al., 1997), whereas c-Fos levels remained unchanged during differentiation. Recent findings
demonstrate that, in differentiating muscle cells the AP-1 complex is mainly formed of heterodimers of
Fra-2 with c-Jun or JunD (Andreucci et al., 2002). We have not focused on the AP-1 dimerization
partners in this study, but the expression of c-Jun, JunD, and Fra-2 suggests that similar heterodimers
are involved in cardiomyogenesis.
AP-1 is mostly activated by MAPKs (Leppä and Bohmann, 1999; Whitmarsh and Davis, 1999). All
three main MAPKs were activated in a sustained manner, but this finding did not prove that they
regulated AP-1 activity or were necessary for the cardiomyocyte differentiation response.  To study the
importance of MAPK activation for AP-1 activity and P19 cell differentiation, we used specific MAPK
inhibitors. Consistent with the results by Davidson and Morange, addition of a specific p38 MAPK
inhibitor to P19 cell cultures totally eliminated the formation of beating cardiomyocytes (Davidson and
Morange, 2000). AP-1 DNA-binding activity as well as c-Jun and Fra-2 expression was inhibited by the
p38 kinase inhibitor, suggesting that AP-1 activation is involved in the p38 MAPK-mediated
cardiomyocytic differentiation of P19 cells. Interestingly, it has been reported that the p38 activity is
required also for skeletal muscle cell differentiation (Zetser et al., 1999; Wu et al., 2000). In addition,
inhibition of ERK pathways diminished the AP-1 DNA-binding activity, and the expression levels of c-
Jun and Fra-2, but it did not affect the differentiation response as efficiently as p38 MAPK inhibition.
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Taken together, the activation of ERK pathways is not essential for the cardiomyocyte differentiation of
P19 cells. However, ERK is required together with p38 for accurate AP-1 DNA-binding activity.
While no chemical JNK inhibitors were available at the time of the study, we created stable cell lines
expressing dominant negative forms of JNKK (SEKAL) and JNK (JNKAPF). SEKAL and JNKAPF cell lines
formed fewer colonies and grew slower than control cells, suggesting that JNK might be involved in the
regulation of P19 cell growth. Later, we confirmed these results by using a commercial JNK inhibitor
SP600125 (data not shown). The role of JNK in cardiomyocyte differentiation of P19 cells could not be
analyzed because of growth retardation. However, inhibition of p38 or ERK pathways did not affect
the proliferation of P19 cells.
To study the link between p38 and ERK pathways and AP-1 activation in more detail, the regulation of
the c-jun gene was examined. Both p38 and ERK inhibition caused downregulation in c-Jun expression
by suppressing the expression of c-jun mRNA. These results encouraged us to study how the c-jun
promoter is regulated in P19 cells.  In addition to the AP-1/ATF site, a MEF2-binding site in the c-jun
promoter was a potential regulatory site of interest. MEF2 protein family members, especially MEF2C,
are activated by p38 and ERK MAPKs (Han and Prywes, 1995; Han et al., 1997), and MEF2C promotes
skeletal muscle differentiation (Zetser et al., 1999). The c-jun promoter regulation was studied by
overexpression of activated forms of MKK6, MKK1 and MKK4 together with a luciferase reporter
under control of a wild type c-jun promoter sequence or promoter sequences that had the AP-1/ATF
site, the MEF-2 site, or both mutated. p38 and ERK, but not JNK, regulated c-jun promoter activation,
which occurred through both AP-1 and MEF2 sites during the differentiation response of P19 cells.
Transcription factors ATF-2 and MEF2C have been shown to activate the c-jun promoter through p38
MAPK in response to serum and EGF (Han et al., 1997; Clarke et al., 1998). Both ATF-2 and MEF2C
are also suggested to be involved in cardiomyogenesis (Skerjanc, 1999; Monzen et al., 2001). The
ATF/AP-1 site was originally recognized as a positive autoregulatory site, binding c-Jun and allowing it
to stimulate its own transcription. While ATF-2 is phosphorylated and activated upon cardiomyocytic
differentiation of P19 cells, c-jun promoter regulation might involve both c-Jun and ATF-2, in addition
to the positive autoregulation of c-Jun (Angel et al., 1988; Monzen et al., 2001). MEF2C seems to be
a well established factor in cardiomyocyte differentiation, and analogous to our results, MEF2 activity
contributes to the regulation of the c-jun gene during muscle cell differentiation (Andreucci et al.,
2002). Recent studies have shown that transcriptional regulation of the c-jun gene is mediated by JNK,
p38, and ERK pathways via the TRE, and by p38 and ERK5 through the MEF-binding site (Kayahara
et al., 2005). JNK-mediated c-Jun and ATF-2 phosphorylation is not necessary for UV- and anisomycin-
induced c-fos/c-jun induction (Hazzalin et al., 1996; Fritz and Kaina, 1999). Similarly, JNK-pathway
did not appear to be involved in the regulation of c-jun expression during cardiomyocyte differentiation
of P19 cells.
The role of ERK as a regulator of c-jun expression, AP-1 activity, and myogenesis is less known than
the role of p38. Nevertheless, our results support reports where UV irradiation, and constitutive activation
of MEK and ras, and c-Jun and AP-1 activation are ERK-dependent (Fritz and Kaina, 1999; Treinies et
al., 1999). The ERK-dependent AP-1 DNA binding and subsequent increase increase in thec-Jun and
Fra-2 expression levels could be explained by a positive autoregulation through the ATF/AP-1 site in
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the c-jun promoter. The MEK/ERK inhibitor used in this study inhibits ERK5 activation in addition to
ERK1/2 activation. ERK5 can phosphorylate MEF2C, and MEF2C activation increases transcription
of the c-jun gene (Kato et al., 1997). The MEF-2 dependent activation of the c-jun promoter could
plausible be mediated by ERK5. Additionally, the ERK5 pathway has been shown to have an essential
role in cardiovascular development, since ERK5-deficient mice die as embryos due to retarded cardiac
development (Regan et al., 2002).
1.2. AP-1 activity is required for cardiomyocytic differentiation of P19 cells
To clarify whether c-Jun/AP-1 was required for cardiomyocyte differentiation of P19 cells, we examined
the differentiation response in P19 cells by expressing the N-terminal truncated form of c-Jun, c-JunbZIP.
c-JunbZIP acts like a dominant-negative mutant of c-Jun by eliminating endogenous AP-1 partners or by
occupying the AP-1 binding site on DNA. When c-JunbZIP was stably transfected into P19 cells, we
observed that the number of beating cell aggregates was significantly reduced and the differentiation
response delayed for 1-2 days. P19 cell proliferation was, however, not influenced by the expression of
dominant-negative AP-1. Taken together, these data suggest that AP-1 activity is required for the
cardiomyocytic differentiation response of P19 cells, but not for proliferation.
Since the dominant-negative form of c-Jun inhibits formation of beating cardiomyocytes, AP-1 can be
regarded as one of the transcription factors involved in the regulation of cardiomyocyte differentiation
of P19 cells. The target genes of AP-1 in cardiomyogenesis are unknown, and major cardiac-specific
genes could be regulated by AP-1. The identification of possible target genes in the future would clarify
the role of AP-1 during cardiomyogenesis. c-Jun could alternatively control the differentiation response
by regulating a suppressor of cardiomyocyte differentiation. Since the expression of dominant-negative
c-Jun in just a small number of cells totally inhibited cardiomyocyte differentiation, we hypothesize that
c-Jun negatively regulates an unknown extracellular suppressor of cardiomyocyte differentiation in P19
cells.
The differentiation of P19 cells into cardiomyocytes in vitro does not imitate the in vivo situation. Still,
it gives insight to the genes that are likely to be involved in the differentiation in vivo. Transcription
factors, such as GATA-4, MEF2C, and Nkx-2, are involved in cardiomyogenesis of P19 cells as well as
in heart development in vivo (Biben and Harvey, 1997; Lin et al., 1997; Monzen et al., 1999). Targeted
disruption of the c-jun gene in mice leads to malformations in the outflow tract (Eferl et al., 1999),
demonstrating the importance of c-jun during heart development in vivo.  The effect of dominant
negative c-JunbZIP on P19 cells was stronger, indicating that other factors, which are absent in P19 cells,
can replace or rescue the lack of c-jun in vivo during heart development. Even though the role of other
AP-1 proteins during cardiomyogenesis is unknown, mice lacking junD develop less adaptive hypertrophy
in heart muscle, while hearts overexpressing junD exhibit a marked hypertrophy, suggesting that JunD
also has a role in heart function (Ricci et al., 2005).
Taken together, our results indicate that a sustained activation of JNK, p38, and ERK MAPKs, and an
increase in AP-1 DNA-binding activity are involved in the differentiation response of P19 cells. c-Jun,
JunD,  and  Fra-2  are  the  major  AP-1  proteins  activated during cardiomyocyte differentiation. c-Jun
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phosphorylation is regulated through JNK, whereas p38 and ERK MAPKs regulate the expression of
c-Jun and Fra-2 proteins. p38 is required for the differentiation of beating cardiomyocytes, and the
dominant-negative form of c-Jun can inhibit the differentiation response. These results suggest that c-
Jun could be regulated through p38 MAPK during cardiomyocyte differentiation of P19 cells.
2. The role of AP-1 during megakaryocytic differentiation of K562 leukemia cells
(II)
2.1. AP-1 activity is ERK- and JNK-dependent during megakaryocytic differentiation
The role of ERKs in hematopoietic differentiation is well known. ERK has been demonstrated to mediate
thymocyte differentiation and subsequent studies have revealed that ERK activity is associated with the
differentiation of progenitor cells along the megakaryocytic pathway (Crompton et al., 1996; Fichelson
et al., 1999). Our aim was to study the role of a putative downstream target of the ERK pathway, the
AP-1 transcription factor. c-fos mRNA has been shown to be expressed in megakaryocytes in bone
marrow in vivo (Mouthon et al., 1992).  Our immunostainings of bone marrow biopsies were consistent
with the mRNA data, and demonstrated that in addition to c-Fos, Fra-1 protein was strongly expressed
in megakaryocytes. The expression of proteins from the Jun-family was very weak (JunD) or undetectable
(c-Jun).
To study the role of AP-1 in developing megakaryocytes, we used the K562 cell line induced to
differentiate along the megakaryocytic pathway. K562 cells are pluripotent human leukemia cells which
can be differentiated along different hematopoietic lineages (Lozzio and Lozzio, 1975). Hemin drives
the differentiation along the erythroid pathway, whereas TPA induces differentiation toward
megakaryocytes (Leary et al., 1987). The megakaryocytic differentiation of K562 cells is a well studied
model system where ERK activity is required for differentiation responses (Racke et al., 1997).
Megakaryocytic differentiation is associated with increased cell surface expression of the platelet and
megakaryocyte specific α
IIb
β
3
 integrin and the collagen receptor α
2
β
1
 integrin (Giltay et al., 1988;
Burger et al., 1992).  The expression of AP-1 proteins c-Jun, JunB, c-Fos, and Fra-1 was induced in
K562 cells during TPA-induced megakaryocytic differentiation. The TPA-mediated increase in AP-1
protein expression was accompanied by an increase in AP-1 DNA-binding activity and in AP-1
transactivation. Consistent with the protein expression levels, the AP-1/TRE complex consisted of c-
Jun, JunD, c-Fos, and Fra-1 proteins. In contrast, during hemin-mediated erythroid differentiation, AP-
1 DNA-binding activity was very weak. Furthermore, c-Fos expression was not induced by hemin and
the AP-1 DNA-binding complex did not include c-Fos.
The MEK-ERK pathway is required for megakaryocytic differentiation of K562 cells, as previously
shown by dominant-negative MEK and ERK expression plasmids and specific MEK inhibitors (Racke
et al., 1997; Herrera et al., 1998). In response to MEK/ERK and JNK inhibitors, the DNA-binding
activity, expression, and phosphorylation of c-Fos, c-Jun, and JunD proteins were reduced. The p38
MAPK inhibitor did not decrease the expression of c-Fos, c-Jun or JunD. In contrast, c-Jun expression
RESULTS AND DISCUSSION
41
levels were further increased by the p38 MAPK inhibitor. Our results demonstrated that in addition to
ERK, also JNK and p38 MAPK are activated during the megakaryocytic differentiation response, but
AP-1 activity is ERK- and JNK-dependent.
2.2. JunD and c-Fos mediate α2β1 integrin expression during megakaryocytic differentiation
Since differentiation of K562 cells induces the surface expression of α
2
β
1
 integrin, we tested whether
MAPKs regulate α
2
 integrin mRNA and protein (CD49b) levels. To date, the enhancer within the α
2
integrin gene is the only megakaryocyte-specific element in which functional AP-1 sites have been
characterized (Zutter et al., 1999). Our and previous results confirmed that the TPA-mediated
megakaryocytic differentiation of K562 cells induced the α
2 
enhancer DNA-binding activity, which was
AP-1 dependent (Zutter et al., 1999). The α
2 
mRNA expression, induced by the TPA-mediated
differentiation response, was regulated by ERK, p38, and JNK MAPKs. In contrast, CD49b protein
expression was regulated only by ERK. The requirement of AP-1 for megakaryocytic differentiation of
K562 cells was studied by overexpression of a dominant-negative AP-1, the c-JunbZIP. The TPA-mediated
expression of CD49b was markedly reduced when c-JunbZIP was introduced into the cells. Further
studies showed that down regulation of c-fos expression by c-fos siRNA almost entirely suppressed the
α
2
 integrin mRNA. Consistent with mRNA studies, CD49b protein expression was also markedly reduced.
To confirm the importance of AP-1 during megakaryocytic differentiation and the effect on α
2 
integrin,
we overexpressed AP-1 proteins in K562 cells. The expression of JunD together with c-Fos increased
CD49b expression independently of upstream signals, whereas neither JunD, c-Jun, nor c-Fos alone
increased the expression of CD49b on the cell surface. Unlike in many differentiation models where c-
Jun plays a key role, the active AP-1 complex in K562 cells seems to contain JunD. Similarly, ERK has
recently been shown to phosphorylate JunD rather than c-Jun in fibroblasts upon EGF-treatment
(Vinciguerra et al., 2004).  Taken together, ERK-mediated expression of  α
2
 integrin is AP-1, particularly
JunD and c-Fos, dependent. Furthermore, both α
2
 integrin mRNA and CD49 protein levels were
upregulated by constitutively active ERK, and downregulated by dominant-negative c-Jun.
ERK and JNK MAPKs can phosphorylate the same sites on Jun-proteins (Leppä et al., 1998; Vinciguerra
et al., 2004). In this differentiation model, the JNK activity seems to be to some extent redundant, even
though ERKs are less effective in phosphorylating Jun proteins than JNKs. JNK activity is not enough
to increase the expression of CD49b on the cell surface, although it regulates c-Jun and JunD proteins.
The Jun- and Fos-induced expression of α
2
β
1
 integrin in K562 cells is solely ERK-mediated. Additionally,
the pseudophosphorylated forms of c-Jun and JunD, c-JunASP and JunDASP, were unable to trigger
expression of CD49b on the surface of K562 cells. JNK activity increased in response to TPA-treatment,
but in contrast to ERK, it does not mediate the expression of c-Fos, which seems to be essential for α
2
integrin expression. On the other hand, JNK and ERK might together regulate JunD expression, which
is required for appropriate AP-1 activity in this differentiation model system.
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3. AP-1 is differentially regulated in response to ERK, JNK and p38 signaling (III,
IV, unpublished)
3.1. Spatial and temporal differences in MAPK and AP-1 activation during NGF- induced
neuronal differentiation and anisomycin-mediated stress.
The MAPK-dependent activation of AP-1 protein c-Jun in rat pheochromocytoma PC12 cell
differentiation and apoptosis has been extensively characterized (Xia et al., 1995; Leppä et al., 1998).
To further understand the differences in AP-1 activation in response to ERK, JNK, and p38 MAPK
signaling, we studied the NGF-induced neuronal differentiation and anisomycin-induced stress response
in PC12 cells in more detail. Anisomycin was originally identified as a protein synthesis inhibitor, and
more recently also as a powerful activator of MAPK signaling (Cano et al., 1994). Since JNK and p38
MAPKs are strongly activated by anisomycin, while ERK is poorly activated, anisomycin is considered
as an inducer of the stress response. Our results show that the proliferation of cells was suppressed in
response to anisomycin, and this appeared to be caused by increased apoptosis.
ERK, JNK, and p38 were activated by both NGF and anisomycin. However, quantitative and qualitative
differences were observed. During the NGF-mediated differentiation response ERK activation was
strong and sustained, whereas in response to anisomycin, ERK activity was weak and transient. On the
contrary, JNK-activation was weaker and faster in NGF-treated cells, as compared to anisomycin
exposure. The data correlate with the studies in which NGF-induced sustained activation of ERK
stimulated differentiation of PC12 cells, whereas the factors that activated ERK transiently did not
enhance differentiation but rather stimulated proliferation (Marshall, 1995). All MAPK inhibitors partially
prevented neurite outgrowth, indicating that ERK, JNK and p38 activities are required for differentiation
response. In contrast, MAPK inhibitors neither prevented nor sensitized PC12 cells to stress-induced
apoptosis. This data show that that apoptosis upon stress response is independent of ERK, JNK and
p38 activities in PC12 cells.
NGF-mediated neuronal differentiation of PC12 cells induces the expression of c-Jun and c-Fos mRNAs
(Sheng and Greenberg, 1990). Our study revealed the activation of AP-1 in response to anisomycin,
which has been poorly characterized previously. The main difference in the induction of AP-1 protein
expression between NGF and anisomycin treatments was that NGF induced a rapid and transient
expression of c-Fos, whereas c-Fos expression was undetectable in anisomycin-treated cells. The
expression of another Fos-family member, Fra-2, was also more strongly induced upon exposure to
NGF than to anisomycin. The slower migrating bands of c-Fos and Fra-2 are most likely due to
phosphorylation of the proteins. There were no significant differences in the expression of c-Jun, but c-
Jun phosphorylation was more prominent and persistent in response to anisomycin. The mRNA levels
of c-jun and c-fos correlated well with the protein expression levels. Consistent with the protein
expression, DNA-binding analyses showed that the DNA-bound AP-1 protein complex mainly contained
c-Jun, JunD, c-Fos, and Fra-2 proteins in NGF-treated PC12 cells, whereas c-Fos was absent in
anisomycin treated cells. The kinetics of AP-1 DNA binding activity correlated also well with protein
levels.
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3.2. c-Fos is a downstream target of ERK signaling during neuronal differentiation of PC12 cells
To study how AP-1 proteins are regulated by MAPKs during differentiation and stress responses, we
treated PC12 cells with NGF and anisomycin in the presence of specific MAPK inhibitors. MEK/ERK
inhibitor reduced the NGF-induced expression of c-Fos, Fra-2, and c-Jun, and fastened the attenuation
of AP-1 DNA-binding activity. This data indicate that ERK activity is essential for sustained AP-1
activity. JNK inhibition suppressed c-Fos expression and AP-1 DNA-binding activity slightly, but had
no effect on c-Jun expression levels. During the anisomycin-induced stress response AP-1 activity was
mainly regulated by JNK and p38 MAPKs. The stimulatory role of p38 MAPKs in anisomycin-induced
immediate-early gene expression has been reported for instance in human Jurkat cells and mouse embryo
fibroblasts (Rolli et al., 1999). In human osteosarcoma cells, anisomycin-induced c-fos mRNA expression
was regulated through p38 and ERK-dependent signaling (Bebien et al., 2003), whereas in certain
cells, JNK and p38 MAPKs are the activators of c-fos transcription and protein phosphorylation (Oldenhof
et al., 2002; Coronella-Wood et al., 2004). Because JNK-inhibitor reduced c-Fos levels in PC12 cells,
it is plausible to suggest that c-Fos is regulated by JNK. Since anisomycin-induced JNK and p38 activities
were unable to induce c-Fos expression, p38 and JNK are insufficient to directly stimulate c-Fos
transcription. Together, the data suggest that instead of directly regulating c-Fos expression, JNK
would rather be involved in the stabilization of pre-existing c-Fos proteins. Our results further demonstrate
that anisomycin induces c-Jun expression in a p38 MAPK-dependent manner, but since JNK inhibition
had no effect on c-Jun expression it might affect the phosphorylation of c-Jun, and in that way affect the
AP-1 DNA-binding activity.
3.3. The role of c-Fos during neuronal differentiation
The increased expression of c-Fos during neuronal differentiation of PC12 cells prompted us to investigate
the role of c-Fos during the NGF-induced differentiation response. Overexpression of c-Fos in PC12
cells induced neuronal differentiation poorly, when compared to c-Jun. However, coexpression of c-
Fos together with c-Jun increased both the length and number of neurites in PC12 cells. Knocking
down c-fos with siRNAs resulted in inhibition of the NGF-mediated differentiation response. Thus, c-
Fos appears to be a crucial factor in the differentiation response, but it cannot induce differentiation
without c-Jun. c-Jun, on the other hand, can induce differentiation very strongly without c-Fos. However,
the role of c-Jun appears to be connected mainly to the onset of neuronal differentiation, since blocking
c-Jun with an antibody affected only the triggering of neuritogenensis, whereas c-Fos is essential
throughout neuronal differentiation (Gil et al., 2004).
Previous studies have revealed that NGF-induced neuronal differentiation of PC12 cells is MEK/ERK
dependent (Cowley et al., 1994). In addition, MEK-mediated differentiation is AP-1 dependent, as
suggested by overexpression of dominant-negative c-Jun, which prevents the differentiation response
(Leppä et al., 1998). The role of c-Fos in neuronal differentiation was further studied using constitutively
active MEK1. Similar to NGF-induced neuronal differentiation, c-fos siRNAs reduced MEK1-induced
neurite outgrowth. These results indicate that ERK-dependent activation of c-Fos is required for NGF-
induced neuronal differentiation of PC12 cells. Similarly, PDGF regulates AP-1 by stimulating the
expression and activity of c-Fos through ERK in fibroblasts, and ERK-dependent activation of c-Fos is
required for PDGF-regulated growth response (Monje et al., 2003). Together, the findings demonstrate
a biologically relevant cellular response, in which growth factor-induced activation of receptor tyrosine
kinases and ERK culminate to activation of c-Fos.
Our findings on PC12 cell responses have shown that the strength and duration of a signal can direct the
biological responses of a cell. Studies on fibroblasts have demonstrated that sustained but not transient
ERK activation mediates S-phase entry (Weber et al., 1997). The binding affinity for a certain TRE is
determined by the dimer combinations and the cellular context. The expression of Jun and Fos proteins
is temporally coordinated in response to various stimuli. Only sustained activation of ERK is essential
to induce the expression of Fra-1, Fra-2, c-Jun, and JunB (Cook et al., 1999). Moreover, during sustained
ERK signalling, c-Fos is phosphorylated and activated, whereas it is unstable during transient ERK-
activation (Murphy et al., 2002). Conversely, it is well established that in PC12 cells NGF induces
sustained activation of ERK, which is sufficient for cell cycle arrest and terminal differentiation, whereas
EGF that activates ERK transiently does not induce differentiation, but rather proliferation (Marshall,
1995). Our studies show that subsequently to sustained ERK activity, which induced c-Fos expression,
increased AP-1 DNA-binding activity is sufficient to stimulate neuronal differentiation of PC12 cells.
On the contrary, the transient ERK expression induced by anisomycin is not sufficient to induce c-Fos
expression.
4. c-Jun has different functions in neuronal differentiation and apoptosis of PC12
cells (III, IV, unpublished)
4.1. Antiapoptotic function of c-Jun is not mediated by conventional AP-1 activity
 c-Jun has been implicated both in neuronal differentiation and in apoptosis. In undifferentiated cells c-
Jun induces differentiation (Leppä et al., 1998). While, in differentiated cells NGF withdrawal triggers
JNK-mediated c-Jun activation, and subsequently cell death (Xia et al., 1995). The latter process can
be prevented by dominant-negative c-Jun (Xia et al., 1995). The differentiation state of the cell contributes
to the outcome of c-Jun activation. To compare the effects of JNK signaling and c-Jun on apoptosis in
undifferentiated and differentiated cells, we initiated apoptosis of PC12 cells by activating the JNK
pathway. Overexpression of the upstream kinase of JNK, the catalytically active MEKK1 (ΔMEKK1),
induced prominent apoptosis in undifferentiated PC12 cells. To examine whether c-Jun contributes to
MEKK1-induced apoptosis of undifferentiated PC12 cells, as it does in differentiated cells, c-Jun was
coexpressed with ΔMEKK1. Unexpectedly, c-Jun did not increase apoptosis in undifferentiated PC12
cells, but prevented it. In addition, the cells expressing c-Jun formed long neuronal sprouts, demonstrating
that c-Jun not only protected against apoptosis in undifferentiated PC12 cells, but also triggered neuronal
differentiation. Interestingly, c-Fos also reduced the number of apoptotic cells when co-expressed with
ΔMEKK1, although the effect was modest in comparison to c-Jun (Figure 5).
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Figure 5. The effects of c-Jun and c-Fos on MEKK1-induced apoptosis and on neuronal differentiation. Percentage
of cells with neurites (left panel) and apoptotic cells (right panel).  The data are the means ± standard errors of three
independent experiments.
JNK phosphorylates c-Jun on serines 63 and 73 and threonies 91 and/or 93 in the transactivation
domain (Derijard et al., 1994; Papavassiliou et al., 1995). To study the role of JNK-dependent c-Jun
phosphorylation in cell survival, we overexpressed c-JunALA, which cannot be phosphorylated by JNK
because the JNK phosphorylation sites have been mutated to alanines. The apoptotic effect of MEKK1
was suppressed when c-JunALA was expressed in PC12 cells, and the effect was equivalent to that
obtained with wild type c-Jun. c-JunASP, the gain-of function mutant where the phosphorylation sites
have been mutated into phosphate-mimicking aspartic acid residues, also promoted PC12 cell survival.
Since the protective effect of c-Jun is independent of phosphorylation, we assumed that exogenously
expressed c-Jun could possibly titrate out activated JNK. However, the δ-deletion mutant, c-Jun∆31-57,
which lacks the JNK-docking site, rescued PC12 cells from MEKK1-induced apoptosis in a similar
manner as wild type c-Jun, indicating that JNK-binding is not required for MEKK1-mediated apoptosis.
We further investigated the importance of distinct functional domains of c-Jun for the antiapoptotic
effect in undifferentiated PC12 cells. By using two mutants in which the DNA-binding activity is impaired
(Figure 6), we found that DNA binding was not essential for rescuing PC12 cells from apoptosis triggered
by MEKK1. Additionally, mutated proteins that could not dimerize with other bZIP proteins still rescued
PC12 cells from apoptosis. Taken together, the antiapoptotic role of c-Jun appears not to require
conventional AP-1 activity, which involves dimerization with other bZIP proteins, DNA binding, and
transcriptional activation of target genes. Dominant negative forms of c-Jun maintained the antiapototic
function of the protein, thus suggesting some unconventional mechanisms in this action. In addition,
JunD and JunB also acted as survival factors in MEKK1-induced apoptosis, and it would be intruiging
to investigate the mechanisms of their action in future studies.
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Figure 6.  Schematic representation of c-Jun mutants used in study IV. The affected sites are marked on the protein,
and the effect explained on the right. The serines (SS) and threonines (TT) phosphorylated by MAPKs are marked in
the N-terminus. The basic region (+++) and bZIP domain (LLLL) are marked in the C-terminus. NLS marks the
nuclear localization signal domain and δ the δ-domain.
4.2. c-Jun functions as a conventional transcription factor during neuronal differentiation of
PC12 cells
Parallel to the antiapoptotic role of c-Jun, we analyzed the impact of the distinct c-Jun domains in
initiating neuronal differentiation. The ability of the phosphorylated form of c-Jun to induce neuronal
differentiation of PC12 cells has been previously reported (Leppä et al., 1998). Expression of wild type
c-Jun in PC12 cells not only protected the cells against MEKK1-induced apoptosis, but also induced
formation of long neurites. Expression of the gain-of-function mutant, c-JunASP, increased the amount
and length of neurites, when compared to wild type c-Jun. In contrast, the mutant that could not be
phosphorylated by MAPKs, c-JunALA, induced neuronal differentiation poorly. In addition, JunD induced
neuronal differentiation of PC12 cells. Surprisingly, the JunD mutant, JunDALA, which cannot be
phosphorylated by MAPKs induced neuronal differentiation more prominently than wild type JunD or
JunDASP. Since the expression level of JunD in normal PC12 cells is relatively high, it is rather surprising
that JunD can induce neuronal differentiation of PC12 cells (Figure 7). We propose that overexpression
of JunD stimulates the expression of c-Jun and/or c-Fos, and in the end, neuronal differentiation is due
to the effects of c-Jun and c-Fos. Why JunDALA further increases neuronal differentiation is unknown
and requires additional studies. In contrast, overexpression of wild type JunB, or JunB mutants, did not
induce neuronal differentiation (Figure 7) even though it was an as effective suppressor of apoptosis as
c-Jun or JunD. These findings are consistent with previous studies reporting that JunB is a weaker
activator of transcription than c-Jun (Chiu et al., 1989).
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Figure 7. Wild-type and mutated Jun proteins induce neuronal differentiation differentially in PC12 cells. Wild
type (WT), ‘gain of function’ (ASP) proteins and mutants which cannot phosphorylated by JNK (ALA/GLU) were
overexpressed in PC12 cells. Percentage of  neuronally differentiatied cells. The data are the means ± standard errors of
three independent experiments.
The δ-deletion mutant lacking the JNK-binding site was able to induce neuronal differentiation, indicating
that JNK-binding is not required for c-Jun to promote differentiation. A mutant that cannot bind to
DNA was unable to form neurites in PC12 cells. Consistently, this mutant does not enhance MEKK-
induced AP-1 responsive promoter activity. Interestingly, a protein with a milder mutation in the DNA-
binding domain that allows the protein to bind to DNA as a heterodimer with c-Fos, but not as a
homodimer, induced neuronal differentiation as well as wild type c-Jun. These results suggest that c-
Jun functions as a heterodimer when it carries out neuronal differentiation. The data are consistent with
results mentioned earlier, where coexpression of c-Jun and c-Fos caused more efficient neuronal
differentiation than expression of c-Jun or c-Fos alone. A mutant protein that cannot dimerize with
other AP-1 proteins resulted in a failure to induce neurite formation in PC12 cells. Taken together,
these analyses indicate that during differentiation of PC12 cells, c-Jun seems to work as a conventional
AP-1 transcription factor, where functional dimerization, DNA-binding, and transactivation domains
are required for neurite formation. Furthermore, MAPK phosphorylation enhances neurite formation in
PC12 cells.
5.  The role of ATF-2 in differentiation and survival (IV)
Based on the results presented above, c-Jun does not appear to be the mediator of MEKK-induced
apoptosis in undifferentiated PC12 cells. This prompted us to investigate which protein would mediate
the apoptotic response. ATF-2 is a bZIP protein belonging to the AP-1 family that can be activated by
JNK and p38 (van Dam et al., 1995). ATF-2 has also been shown to be phosphorylated during neuronal
apoptosis  of  PC12  cells  treated  with  okadaic  acid  and  in  the rat brain following hypoxic-ischemia
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(Walton et al., 1998). Expression of constitutively active ATF-2 increased PC12 cell apoptosis markedly.
Expression of wild type ATF-2 also decreased the number of surviving cells, whereas a mutant protein
that cannot be phosphorylated by JNK failed to induce apoptosis. However, ATF proteins, mutated and
wild type, were unable to induce neuronal differentiation of PC12 cells. On the other hand, c-Jun
reduced ATF-2-induced apoptosis, demonstrated by coexpression of constitutively active ATF-2 and c-
Jun. Interestingly, a c-Jun mutant that cannot dimerize was able to lower the number of apoptotic cells
triggered by constitutively active ATF-2, suggesting that c-Jun does not interfere with ATF-2 activity
by binding. Competition of cofactors could be an explanation, even though the isolated transactivational
domains of c-Jun are not able inhibit apoptosis alone.
Expression of ATF-2 and c-Jun into PC12 cells through titration showed a dosage-dependent effect of
ATF-2 in the onset of apoptosis. The role of c-Jun in the protection against apoptosis as well as in the
induction of neuronal differentiation was dosage-dependent as well. Based on the results presented
above, we propose that a balance between c-Jun and ATF-2 activity influences the cell fate between
neuronal differentiation and apoptosis.
Figure 8. The multiple functions of AP-1 in the control of cardiomyocytic, megakaryocytic, and neuronal
differentiation, and during apoptosis.
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CONCLUSIONS
In the present studies, the role and regulation of AP-1 transcription factor during cardiomyocyte,
megakaryocytic, and neuronal cell growth and differentiation was revealed in cell culture differentiation
models. In addition, the role of c-Jun in differentiation and apoptosis was further explored by using
mutants of the c-Jun protein. The multiple functions of AP-1 presented in this study are shown in Figure
8. The main conclusions made from these studies are:
1. p38- and ERK-dependent AP-1 activity is required for the cardiomyocyte differentiation of P19
cells, while JNK activity is essential for P19 cell proliferation.
2. AP-1 activity during megakaryocytic differentiation is ERK- and JNK-dependent, but only ERK
activity is essential for differentiation. α
2
β
1
 integrin expression is mediated by ERK through c-Fos
during megakaryocytic differentiation of K562 cells.
3. Sustained ERK and c-Fos/AP-1 activities mediate neuronal differentiation of PC12 cells, whereas
neither the activation of MAPKs nor the transient activation of AP-1 are essential for the anisomycin-
induced stress response.
4. c-Jun protects undifferentiated cells from apoptosis. While JNK binding, phosphorylation,
dimerization, and DNA binding are not required for the antiapoptotic role of c-Jun, dimerization
and DNA binding of c-Jun are essential for the neuronal differentiation response.
5. ATF-2 mediates apoptosis in undifferentiated PC12 cells. A balance between c-Jun and ATF-2
determines whether cells undergo neuronal differentiation or apoptosis.
In conclusion, these studies imply that even though AP-1 is activated in diverse differentiation models,
the composition of the AP-1 complexes and their regulation vary considerably in individual cells. Many
factors other than AP-1 contribute to the final outcome of cellular behavior. These studies reveal some
of the complexity of the regulation and functions of AP-1 transcription factor during cellular differentiation
and survival.
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